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 Introduction: 
 Helicobacter pylori is a less studied bacteria in our country. Association of 
virulence factors like cagA and vacA subtypes to the disease manifestations and 
resistance profile to the commonly used first line drugs varies widely among the 
geographical regions. For effective treatment of patients, we need to know these 
epidemiological profiles of H.pylori for every individual region. Also, among various 
methods to detect H.pylori infection, Rapid urease test (RUT) has remained the most 
widely used one. The efficacy of the various commercial kits and in-house preparations 
must be evaluated before using them as a routine diagnostic tool. 
Aim:  
 To know the prevalence, recognize the specific gene variants and their association 
with the virulence state and identify the drug resistance among H.pylori in our 
population. 
Material and Methods: 
         Gastric biopsy samples obtained from 165 patients with gastroduodenal diseases 
were included in the study. RUT and culture was compared against PCR for glmM gene. 
CagA and vacA s and m subtype status analysis of the infected patients was performed by 
PCR and their association with endoscopic findings was studied. Clarithromycin and 
Amoxicillin susceptibility testing were performed on the isolates using E-strips. 
 
 Result: 
 Prevalence of H pylori was found to be 37 percent. The RUT had a sensitivity and 
specificity of 93.4% and 90.4% respectively. There was a statistically significant 
association between presence of cagA & vacA s1 subtype and peptic ulcer disease rather 
than the non ulcer dyspepsia (p<0.05). In this study the resistance to Clarithromycin and 
Amoxicillin was 7.62% and 15.38% respectively.  
Conclusion:  
RUT used in this study would serve as a better screening test. CagA and vacA s1 
positive strains are the virulent ones in this locale. Usage of Clarithromycin and 
Amoxicillin can be continued as first line drugs in H.pylori eradication therapy in our 
population. 
Keywords: H.pylori, cagA gene, vacA gene, RUT 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
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Helicobacter pylori is the causative agent for variety of gastrointestinal 
disease-Chronic antral gastritis, Gastric ulcer, Duodenal ulcer, Gastric 
adenocarcinoma and Non Hodgkin’s Lymphoma. Most of the infected patients 
remain asymptomatic. Disease manifestation is known to be associated with 
pathogenicity factors like proteins coded by cagA and vacA gene. However, there 
is a wide variation not only in the prevalence of these pathogenicity islands (PAI) 
in different ethnic groups, but also their association with clinical manifestations (1). 
Studies from different parts of the world show different strains to be prevalent in 
their regions. In Iran, strains with vacAs1m2 genotype and cagA positivity are 
more prevalent and associated with Peptic Ulcer disease. (2,3) In Turkey, s1am2  
and s1am1 both occur in equal rates, but cagA  positivity is more with s1m1 
type.(4) cagA positivity is found to be 70% in India and Bangladesh, 56% in 
Pakistan, 70-76% in middle eastern countries and 90% in Japan.(5,6) In Jordan, 
predominant genotypes are s1m1 and s2m2. In northeastern part of Mexico , 
cagA+vacs1m1 strain are found mostly and are associated with intestinal 
metaplasia.(7) The study done by Chattopadhyay et al at  National Institute of 
Cholera and Enteric Diseases found that in India cagA+ s1m1 strains are 
predominant. Though the pattern is similar, these strains are associated with peptic 
ulcer disease in India.(8) Another study by Udhayakumar et al from south India 
found cagA positivity of 96% and vac m2 to be the predominant one in Chennai. (9) 
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Study by Xue FB et al and Eslick GD et al found that H pylori is a 
definitive risk factor for gastric carcinoma.(10,11) Complete remission of low grade 
gastric MALT lymphoma was achieved in 60%–80% of patients following 
eradication of H.pylori (12,13). Studies support the role of H. pylori in the 
development of gastric carcinoma and indicate that anti-Helicobacter 
pylori therapy may be effective in preventing gastric cancer. 
 
 Helicobacter pylori is also developing drug resistance and the prevalence 
of resistant strains are increasing at an alarming rate due to widespread use of 
antibiotics like Macrolides, Quinolones and Metronidazole. Systemic review of 
studies done from 2006 - 2009, by De Francesco V et al concluded that the overall 
antibiotic resistance rates were high for metronidazole (26.7%) followed by 
Clarithromycin (17.2%) and levofloxacillin (16.2%). Resistance to amoxicillin 
was 11.2 percent.(14) One of the multicentric study conducted in India recorded a 
high resistance rate to three most commonly used drugs- metronidazole (77.9%), 
clarithromycin (44.7%) and amoxycillin (32.8%). Multiple resistances were seen 
in 43.2% isolates. Resistance to the drug metronidazole was high in Lucknow, 
Chennai and Hyderabad and moderate in Delhi and Chandigarh. (15) Study by 
Ahmed et al in Hyderabad shows that 96% - 97% of the clinical isolates were 
sensitive to Tetracycline and ciprofloxacin, resistance to Amoxycillin,  
Clarithromycin and metronidazole was 80%, 76% and 100% respectively 
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(16).These are the first line drugs used routinely at our hospital. Though there is a 
need to know the sensitivity of our strains for effective management of these 
patients, difficulty in cultivating this fastidious organism makes it challenging. 
 
Since H pylori genotypes vary from population to population, specific 
study is required to find the most prevalent genotypes and the commonest diseases 
associated with them to decide on the effective management. Also, resistance rates 
of the commonly used antibiotics have to be studied in order to choose the right 
treatment regime for the locale.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM & OBJECTIVES 
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AIM: 
To study the prevalence of virulence factors of H pylori and their 
association with disease pattern among patients in a tertiary care hospital. 
 
 
OBJECTIVES: 
1. To isolate and characterize H pylori from gastric biopsy samples of patients 
attending the gastroenterology outpatient clinic at PSG Hospitals. 
2. To compare the detection methods such as rapid urease test and culture 
against PCR in the diagnosis of H pylori infections. 
3. To identify the cagA and vacA gene variants and their association with the 
virulence state. 
4. To identify the prevalence of drug resistance among H pylori isolates using 
E test. 
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HISTORICAL PERSPECTIVES: 
Over 100 years ago a Polish Clinical Researcher Prof W Jawroski described 
the presence of spiral shaped micro organisms in the human stomach. In 1893, G. 
Bizzazero described similar organism in animals which turned out to be 
Helicobacter felis, H. canis and H. heilmannii. (17)  But their presence was not 
really taken seriously until the late 1970s when Robin Warren a Pathologist 
noticed the appearance of these bacteria in the gastric mucosa of inflamed tissues. 
This discovery changed the wide spread notion that chronic inflammation of 
stomach caused by immune reactions may well be caused by an infection. 
In 1940, Freedberg- Anatomists and Baron-pathologists noticed spiral 
organisms in the carcinomatous human gastric mucosa now and then. They found 
spiral shaped organism in about 40% of resected specimens. But, they could not 
establish the association because, these bacteria disappeared with rigorous 
chemotherapy in these patients. (17) 
Later in 1950s, Susumu Ito of Harvard Medical School made the first 
detailed description of the appearance of gastric mucosa under the electron 
microscope. Ito's photographs of the gastric corpus showed "spirilli" in some of 
his material. In 1967, he published a photograph showing enlarged H. 
pylori within a parietal cell gland. For the first time the sheathed flagella and 
typical spiral morphology was clearly demonstrated in these pictures (18).  
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In the mid-1970s, Steer and Colin-Jones made several failed attempts to 
culture H.pylori. Finally Robin Warren with Barry J Marshall, succeeded in 
cultivating this bacterium in an artificial medium for the first time in 1983 and 
named it Campylobacter pyloridis because it resembled the then known 
pathogenic bacteria of the Campylobacter genus in the intestinal tract. (17, 19) Later 
a new genus called Helicobacter was created since it did not fit into the genus 
Campylobacter. In 1983, McNulty and Skirrow succeeded in culturing it from a 
gastric ulcer patient in England. (20) 
In 1983, at the Centre for Digestive Diseases, Borody came up with the first 
functioning Triple Therapy for eradication of H. pylori and cure of Duodenal 
Ulcer. This combination comprised of Bismuth sulfate, Tetracycline and 
Metronidazole. (21) Studies by Rauws and Tytgat, Coghlan et al and Graham et al 
proved that H. pylori eradication therapy  cured  peptic ulcer. (22-24) 
Of the 100 patients studied by Marshall and Warren, patients who were 
found to be infected were more than 65% and almost all of them had gastritis. 
Almost 80- 100% of the patients who had duodenal ulcer and gastric ulcer were 
infected. Other patients who had ulcer without H. pylori were on nonsteroidal anti-
inflammatory drugs. This finding motivated several researches all around the 
world and similar results were found in several countries within few years. (19) In 
the ensuing 5 years, several double-blind trials were conducted to study the 
infection eradication rates of the available therapies like bismuth with any one 
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anti-H.pylori antibiotic. Results were poor, with only one-fourth of the patients 
achieving eradication. (22-24) 
MILESTONES IN H.PYLORI STORY 
1893- Bizzozero reported existence of gastric spiral organisms in healthy dogs. 
1906 -Krienitz first observed the spiral shaped organisms in human stomach 
1938 -Doenges observed spiral bacteria in the gastric mucosa of about 50% of 
human stomach examined in autopsy 
1940- Freedberg and Barron reported similar organisms in 37% of gastrectomy 
specimens from patients with peptic ulcer or carcinoma. 
1975- Steer and Colin Jones came close to identification of Helicobacter pylori 
and its association with gastritis, but they misinterpreted the culture results and 
concluded that the organism was pseudomonas. 
1982- Warren and Marshall were the first to culture, identify and establish the 
association   between presence of the organism in gastric mucosa and occurrence 
of histological gastritis. 
1984- Organism was named as Campylobacter pyloridis by Marshall et al. 
1987- Eradication of H.pylori proved to be to a long term cure of duodenal 
ulceration. 
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1989- The Genus ‘Helicobacter’ was created 
1994- The International agency for research on Cancer working group WHO 
defined Helicobacter pylori as a grade –I or definite human carcinogen.  
PHYLOGENY AND NOMENCLATURE:  
          Vandamme and associates placed Helicobacter under the phylogenetic 
group- rRNA superfamily VI along with Campylobacter, Arcobacter and 
Wolinella (based on DNA-rRNA hybridization, 16S rRNA sequence analysis and 
immunotyping analysis).  Among this superfamily Helicobacter falls under RNA 
cluster III. (25) 
           Helicobacter pylori comes under the epsilon subdivision of  Proteobacteria, 
and order Campylobacterales. Skirrow proposed to name the new gastric bacteria 
as Campylobacter pyloridis and the culture from the Royal Perth Hospital 
13487(NCTC 11637) was designated as type strain. (26) 
           A new classification was proposed and H. pylori was placed under the 
family  Helicobacteraceae and genus Helicobacter.  (27) The genus Helicobacter 
comprises of 23 species. Some of the medically important species are H.pylori, 
H.cinaedi, H.fennelliae, CLO-3, Helicobacter Sp. Strain flexispira and 
H.heilmannii (Gastrospirillum hominis).  Among these only H.pylori and 
H.heilmannii are isolated from the gastric mucosa. Other species are recovered 
either from the rectal swab or feaces .Other nonhuman Helicobacters seen in 
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rodents and other mammals are H.canis , H.bilis, H.bizzozeronii, H.felis, 
H.hepaticus, H.muridarum, H.mustelae, H.nemestrinae, H.pametensis and 
H.pullorum .They cause gastritis in their host animals. 
           Helicobacter pylori was initially called Campylobacter pyloridis and then 
Campylobacter pylori. On 16S rRNA study it was found to be different from 
Campylobacter. Henceforth the new Genus Helicobacter with H.pylori being the 
first species was created. Later other species were identified. (25,28) 
          Helicobacter pylori can be differentiated from Campylobacter by its 
multiple sheathes flagella, its strong urea hydrolysing property and its fatty acid 
profile (high percentage of 14:0 acid, low 16:0 acid and the presence of 3-OH-18:0 
acid) (18)  
MORPHOLOGY: 
H. pylori is a Gram-negative bacteria.  It appears as an s-shaped or curved 
rod with 1 to 3 turns in gastric biopsy specimen and fresh isolates which is 
described as Seagull appearance by some authors. It measures 0.5-0.9 µm wide 
and 2-4 µm long. Cells appear as singly curved rods owing to the less obvious 
spiral forms. Other rare forms reported in culture includes spherical, U form, V 
form (ox-bow) and straightened forms. 
It is a non spore forming bacteria. H. pylori are motile with six polar 
sheathed flagella with a covering that is continuous with the outer membrane of 
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the cell wall. Though they are actively motile, cultures may appear to be non 
motile in hanging drop preparations. The normal configuration of flagella is found 
to be seven by freeze-fracture ultra structure studies. Each flagellum is 30 nm in 
diameter with a filament of 12-15 nm. Some flagella have distinctive terminal 
bulbs with no special function. Electron microscopy shows that external to the cell 
wall there is a 40 nm thick glycocalyx (capsule-like polysaccharide rich layer), 
which is thicker in vivo than in cultured bacteria. 
In older cultures, H. pylori undergo morphological change from bacillary to 
coccoid form with an associated loss in cultivability. These forms are viable but 
more resistant and dormant. This is a temporary adaptation to a hostile 
environment - stress caused by nutrient deprivation, antibiotic exposure or 
extended incubation. It is hypothesized, but not yet proved, that these coccoid 
forms can revert to an infectious bacillary form under appropriate conditions.  
GENETICS: 
  H.pylori has a single circular DNA with a mean size of 1.71 Mb ranging 
from 1.40-1.73 Mb. Its base composition is in the range of 35-37 mol% G+C. 
Despite evidence showing re-arrangements in gene order, DNA-DNA 
hybridizations shows a high level (1>65%) of sequence homology between strains. 
The complete sequences of the genomic DNA from several strains have been 
determined. Extra chromosomal plasmid DNA is found in half of the strains, 
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although the type strain (NCTC 11637) is plasmid free. Plasmid varies in size 
from 1.8 to 63 kbps.  
Helicobacters have a typical cell wall of Gram negative bacteria made of 
Lipopolysaccharide (LPS) attached to the outer membrane, a peptidoglycan layer, 
and an inner cell membrane. The major cellular fatty acids are tetradecanoic acid 
and octadecanoic acid, with smaller amounts of hexadecanoic acid and 3-
hydroxydecanoic acid. The main respiratory quinone is menaquinone-6 but 
thermoplasmoquinone-6 is lacking. These characters exclude this bacterium from 
Campylobacter. (20) 
LPS of about 80% of strains express Lewis x and y blood group antigens 
which are not found in other Gram-negative bacteria. Structural analysis of the O-
polysaccharide chains resemble fucosylated Lewis x and y antigens. Example: the 
O-chain of the type strain (NCTC 11637) mimics Lewis x antigen. This LPS helps 
in attachment of bacteria to human gastric epithelial cell. (20) 
HABITAT: 
H.pylori has been isolated from gastric and duodenal biopsies. It colonizes 
the mucus layer of surface epithelia in a patchy fashion. (29) They are located 
predominantly in the antrum followed by corpus and bulb of the stomach. They 
are densely distributed around the lumen of gastric pits, but when subjected to 
acidic stress, they extend into the lumen of gastric glands. (30) 
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CULTURE OF HELICOBACTER PYLORI: 
Transport media: 
 Transport medium is used mainly to prevent exposure to atmospheric 
oxygen and also to avoid drying of biopsy specimen. Survival is better when 
transported at 4oC and plated immediately. Some of the media are Brucella broth, 
Thioglycolate broth, Stuart’s medium, Carry and Blair medium. A biphasic 
medium has also been described to give better result. (20) 
H. pylori is a microaerophilic organism, growing best in the presence of 5% 
oxygen along with 5-10% CO2 on blood containing non selective media eg: Oxoid 
brain heart infusion agar (BHI) and 5% horse blood agar enriched with 1% 
IsoVitaleX, which is a well defined supplement having vitamin B,2, L-glutamine, 
L-cysteine, and various other growth promoting compounds. These media can be 
made selective by adding antibiotic supplements. It has a respiratory type of 
metabolism. The optimum temperature for growth is 37°C.  (18,20)All strains can 
grow within a narrow temperature range of 33- 40°C, whereas growth is poor at 
temperatures both below and above the range and none grew at 25°C. H. pylori 
grows over a wide pH range (5.5-8.5), but optimum growth occurs between pH 6.9 
and 8.0. H. pylori do not tolerate low pH in vitro. It takes a minimum of 3-5 days 
for an observable growth in a well defined media. 
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List of media that can be used for culture: 
Marshall et al, during their first isolation used BHI chocolate agar 
supplemented with 7% horse blood. (19) Several nutrient-rich media such as tryptic 
soy broth, brucella broth/agar, brain heart infusion broth/agar, Columbia blood 
agar and Mueller-Hinton broth/agar (MHB) has been shown to support the  growth 
of H.pylori.  
Fetal calf serum (FCS) is one of the most commonly used supplements. 
Solid media are usually supplemented with blood and serum. Other typical 
supplements added to growth media include lysed erythrocytes or hemin, yeast 
extract(YE), peptone, IsoVitaleX, starch, ferrous sulfate plus sodium pyruvate 
(FP), cyclodextrins,  mucin, cyanobacterial extract.(31)  Egg yolk emulsion has also 
been found to be a good supplement. Although some of these enhance the growth 
of H. pylori, the serum or blood in the culture media can’t be replaced. 
 Listed below are some of the preparations used for culturing H. pylori (32- 34) 
  
1. The formula of Goodwin et al. (GDW agar) contained brain heart infusion 
agar, 7% whole defibrinated horse blood, and 1% IsoVitaleX.  
2. The medium of Glupczynski et al. (GLU agar) contained brain heart 
infusion agar, 10% horse serum, 0.2% charcoal, 1% yeast extract, and 40 
mg of triphenyl tetrazolium chloride per liter.  
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3. Columbia blood agar as described by Dent and McNulty (D&M agar) 
consisted of Columbia agar and 7% lysed horse blood.  
4. EYE (Egg Yolk Emulsion) agar consisted of Columbia agar, 10% EYE, 1% 
IsoVitaleX, and 40 mg of triphenyl tetrazolium chloride per liter. 
5. Brain heart infusion egg (BHIE) agar was made from brain heart infusion 
agar with 10% EYE and 1% IsoVitaleX 
6. BBA with 7% sheep blood. 
7. HPBSA 
8. Modified Thayer Martin agar. 
The following antibiotics supplements are used in different combination to avoid 
growth of contaminants.  
Vancomycin 3-6 mg/l 
Amphotericin B 2-6 mg/l  
Trimethoprim 5-20 mg/l 
Colistin 25,000IU/l 
Cefsulodin 5 mg/l 
Skirrow’s antibiotic supplement is the most commonly used one in day to 
day practice. It contains a combination of vancomycin, Polymyxin B and 
Trimethoprim. 
Several liquid media has also been used for mass production of bacteria for 
storage, antigen preparation and other purposes. (35, 36) 
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BIOCHEMICALS: 
 
H. pylori are inactive in most of the conventional biochemical tests. 
Carbohydrates are neither fermented nor oxidized. H. pylori tests positive for 
catalase and cytochrome oxidase but the most notable features are its high level of 
urease and alkaline phosphatase activity. Helicobacter pylori are a homogeneous 
species in its enzyme profile, with few exceptions of some minor strain differences 
in amino peptidase and other preformed enzyme activities. Very rare reports of 
catalase and urease negative strains have been quoted but isolation of such strains 
from a biopsy material is uncommon. An important strain to strain variability is 
their difference in vacuolating cytotoxin.  
 Both H.pylori and Helicobacter sp. strain flexispira are strong urease 
producers. Main differentiating feature between them is their susceptibility to 
cephalothin. H.pylori is inhibited by cephalothin whereas Flexispira strain is 
susceptible. H.pylori is resistant to nalidixic acid too. (18, 37) 
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Reactions shown by Helicobacter pylori 
Catalase Positive 
Oxidase Positive 
Urease Positive 
Alkaline phosphatase test Positive 
Acid phosphatase test Positive 
Naphthol-AS-Bl-phosphohydrolase test Positive 
Leucine arylamidase test Positive 
Gamma glutamyl transpeptidase test Positive 
Hippurate hydrolysis  Negative 
Nitrate reduction  Negative 
Indole Negative 
Arylsulphatase test Negative 
Growth with 1 % and 3.5% NaCl Negative 
Indoxylacetate hydrolysis test Negative 
Growth at 42oC Negative 
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VIRULENCE & PATHOGENICITY: 
FACTORS ASSOCIATED WITH COLONIZATION OF GASTRIC MUCOSA: 
 Neutralization of acid 
 Motility and pH taxis 
 Adherence to mucin and gastric epithelium 
UREASE 
Enzyme urease plays a major role in acid neutralization. It constitutes up to 
10% of the total cell protein. This is an important enzyme in bacterial physiology 
as it is needed for survival in an acidic environment. This enzyme is composed of 
two subunits, UreA and UreB, which are encoded by the ureAB genes. 
  It’s a constitutive enzyme found both in cytoplasm as well as the surface of 
the bacteria. Surface urease brings down the environmental acidity. Cytoplasmic 
urease decreases the acidity in periplasmic space. (38) 
 In the ureIEFGH operon, ureI gene is the first gene. It codes for UreI 
channel transporter. Urea moves into cytoplasm through this protein. The other 
genes of the operon code for accessory proteins involved in urease activity. 
Through the UreI channel, urea is transported into the periplasmic space, making it 
available to the cytoplasmic urease. This results in buffering of the periplasm and 
making the survival of this pathogen in an acidic environment easier. (39) 
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OTHER MECHANISMS INVOLED IN pH balance: 
FUNCTION GENE 
Production of ammonia Ami E, Ami F and Rocf ( aliphatic 
amidase, Formamidase, Arginase) 
Regulation of ammonia synthesis Nix A, Nik R and ars RS 
 
H pylori has a H+/K+ ATPase proton pump of P type, similar to the one 
normally found in the parietal epithelial cells. This bails out any proton that gets 
into the cell, thus helping to maintain a proton gradient across the bacterial cell 
membrane. 
FLAGELLA: 
Flagella are made up of flagellin subunits which are encoded by genes - 
flaA and flaB. The bacteria move through the mucus to reach the epithelial surface 
as the pH there, is approaching neutral. The flagella act like screws in propelling 
the bacteria through mucus. When the non-motile mutants were tested for their 
ability to infect gnotobiotic piglets, they were shown to be deficient in 
colonization of the stomach. This proved the significance of motility in 
colonization and persistence of infection in the host. (40) 
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Bacterial flagella are generally potent antigens, activating the innate 
immune system. Owing to the modifications in the flagellin structure, Toll like 
Receptor-5 does not recognize H. pylori flagellin efficiently. Hence it is a poor 
activator of innate immunity, yet another feature contributing to the persistence of 
infection in the host. (41) 
THIOREDOXIN REDUCTASE: 
This enzyme breaks down the mucin and helps penetration of the bacilli 
from the surface of mucus into deeper layers. This is encoded by hp825 coding 
sequence. 
pH TAXIS: 
H. pylori sense the pH gradient, so that it can move away from the acidic 
surface of mucus, toward the epithelial surface. This sense of a chemical gradient 
in coordination with the flagellar determines the direction of the bacterial 
movement.  When the Genes involved in pH sensing i.e. cheY (42) and tlpB (43) are 
mutated these strains are defective in the colonizing the stomach. 
ADHESINS: 
Adhesion of Helicobacter to the gastric epithelium is mediated by numerous 
outer membrane proteins of the bacteria. Their expression is regulated in response 
to environmental cues.(44,45) Examples of some adhesins are the Adherence-
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associated lipoproteins (AlpAB), Sialic acid-binding adhesin (SabA), Blood group 
antigen-binding adhesin A (BabA) and OipA 
 
 
PROTEIN FUNCTION 
alpAB Adherence, colonization and Initiation of proinflammatory 
signaling cascades 
sabA/sabB Binds to sialyl-Lewis x and a antigens on gastric epithelial cell 
babA Binds to Lewis b (Leb) blood group antigen on the human gastric 
epithelial cell 
oipA For bacterial adhesion. Associated to cag status and development 
of peptic ulcer 
Trx Colonization of gastric mucosa through disruption of structure of 
mucin 
napA Bacterial adhesion and modulation of the immunological response 
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FACTORS HELPING IN COPPING WITH IMMUNE RESPONSE: 
1. Bacterial location within the lumen away from the reach of IgG & 
IgM. 
2. Shedding of large quantities of antigens which mop-up the IgA 
antibodies in the lumen  
3. Presence of feeble endotoxins which does not stimulate immunity 
effectively. 
4. Having the enzyme catalase it neutralizes any hydrogen peroxide 
released. 
5. Heat shock proteins produced by H.pylori under stress conditions, 
act like chaperons, protecting the protein molecules and helping the 
bacteria survive in harsh environment. 
FACTORS ASSOCIATED WITH DISEASE: 
Cag PAI: 
The cagPAI is a genomic region found in the glutamate racemase gene (glr) 
of   H. pylori. It is approximately 40 kb in size. It is involved in expression of the 
type IV secretion system and translocation of bacterial products to the host cell. 
The cagA gene is a marker for the presence of cagPAI. It encodes for CagA, the 
first proteins considered to be a virulence factor of H. pylori. (46, 47) 
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CagA has a unique structure compared to other known proteins. CagA 
positivity has been widely accepted as a predictor of severe gastritis and an 
increased risk of peptic ulcer disease, atrophic gastritis and gastric cancer, 
particularly in western populations. (48) About 60-70 per cent of H. pylori strains in 
the West were found to be cagA+ and these strains were associated with Duodenal 
ulcer and Gastric carcinoma. (49) However, more than 90 per cent of H. pylori 
strains in Asia are cagA+ irrespective of their disease. (9, 50) cagA positivity rate in 
Indian population is found to be generally more than 50%. (51) 
The Type IV secretion apparatus translocates cagA protein into the 
cytoplasm of the gastric epithelial cells. CagA proteins are phosphorylated by host 
kinases in the cell and CagA interacts with the host signaling molecules such as 
the Src kinase, tyrosine phosphatase and Crk adaptor protein. This brings about 
changes in the host epithelial cell.(52)  
Cag A brings about cell elongation processes called as the hummingbird 
phenotype, Cytoskeleton rearrangement, loss of epithelial barrier function by 
disrupting tight junction and loss of cell polarity. CagA helps in the activation of 
NF-κB, the proinflammatory transcription factor. (53)  
The cagE gene is a more accurate marker of cagPAI than cagA. Cag E 
induces IL-8 production by host cells. It’s known to be associated with peptic 
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ulcer disease. The cagT gene codes for an extracellular lipoprotein situated at the 
base of the Type IV Secretion System. (54) 
In a given strain, the cagPAI can undergo partial or complete deletions. 
Similarly Cag PAI positive and negative strains can co exist in same patient. The 
balance between these strains is a significant contributing factor for colonization 
and persistence of Helicobacter pylori in the host. (55) 
Vacuolating Cytotoxin: 
The vacA is universally present in H. pylori and it is encoded by VacA 
gene. The 140 kDa precursor protein of vacA is cleaved to yield a mature toxin 
and secreted in to the host environment. Mature protein has two parts, free and 
bound part. The free molecule is released into the environment and its function is 
not known. The bound part remains in contact with the bacterial cell surface and is 
more toxigenic. Consequent to the contact with the gastric epithelium, this bound 
part is transferred to host cells. (56)  This toxin creates pores in host-cell membranes 
through which anions and small molecules like urea leaks out. (57-59) Formation of 
large acid vacuoles is induced by this toxin. It disrupts intercellular tight junction 
in gastric epithelial calls.  It induces apoptosis of gastric epithelial cells by 
damaging the mitochondrial inner membrane and causing efflux of cytochrome C. 
(61) It blocks various steps in the pathway of immune response like antigen 
 24 
presentation to T cells, activation and maturation of phagosomes in macrophages. 
(61, 62) 
The vacA is a polymorphic gene, showing variability in the nucleotide 
sequence in the three following regions: signal sequence (s), intermediate (i) and 
middle regions (m). There are two types of each sequence- signal sequence (s1 and 
s2), middle sequence (m1 and m2) and intermediate sequence (i1 and i2). Hence 
the vacA gene of a given strain can have any one combination of s and m region 
sequence types. Literature cites that the s2/m1 combination is rare. (63) 
Specific vacA genotypes are associated with level of toxin production and 
clinical diseases like Peptic ulcer disease and Gastric Carcinoma in different part 
of the world. (50) However, study by Udhayakumar et al showed significant 
association between the cagA and m2 of vacA among gastric ulcer patients also 
suggesting Helicobacter pylori strains with the vacA m2 region were predominant 
in Chennai, South India. This study also showed that studying the cagA gene from 
biopsy specimens through PCR has a potential value. (9) Both s1m1 and s1m2 
variants of vacA are known to be associated with gastric diseases like ulcers and 
cancer especially in western countries. (64, 65) The degree of illness and the pattern 
of association vary with ethnicity. (10) 
The biological activity of VacA is blocked by a short N-terminal extension 
in s2 forms. (11) Hence H. pylori strains that harbour s2 genotype encode proteins 
with low toxicity and are not frequently associated in gastric diseases. (66, 67) 
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The vacA shows polymorphism related to the ‘i’ region. This region codes 
for restriction endonuclease. VacA s1m1 and s2m2 types were invariably typed as 
i1 and i2, respectively. Only the vacuolating activity of s1m2 and s2m1 strains 
were found to depend on the ‘i’ type. Recent studies show that vacA i1 has 
significant association with adenocarcinoma and peptic ulcer. (68, 69)   
The cagPAI and vacA are located separately in the genome of Helicobacter 
pylori. Yet the presence of cagA and active s1 form of vacA positive H. 
pylori strains in a patient seems to be more associated with gastritis, peptic ulcers 
and gastric cancer. (67, 70) 
 
DISEASES CAUSED BY H pylori: 
Infection with H.pylori produces a highly variable picture which is 
influenced by variety of factors like dietary habits, lifestyle, host immunity, 
virulence of the infecting strain. Colonization of gastric mucosa with H.pylori 
invariably results in inflammatory response. Only in few patients this leads to 
severe diseases like peptic ulcer, MALT lymphoma, gastric adenocarcinoma, etc. 
Rest others have mild asymptomatic gastritis which goes unnoticed. 
Chronic Gastritis: 
 Gastritis is of two major form Type A and B. Type A is an autoimmune 
disease where antibodies are produced against acid secreting parietal cells. 
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Inflammation is confined to corpus of stomach predominantly. Type B gastritis 
affects the gastric antrum involving the mucus secreting cells. Association of 
H.pylori and gastritis is found to be 70-90%. (71) 
Peptic Ulcer: 
Majority of patients with duodenal and gastric ulcer are infected with 
H.pylori. Majority of the ulcers are in the first part of duodenum and the lesser 
curvature of stomach. (72) Studies done in different geographic locations point 
towards the same. Eradication of infection with combination therapy has proved to 
heal the ulcers. (73) Peptic ulcers occur more commonly in men than in women 
with the average ratio of 18:1 in developing countries .This indicates the influence 
of environmental factors on disease manifestations. (74) 
Gastric Carcinoma: 
This is the second common cause of fatal malignancy in the world 
accounting for more than a half million deaths annually. H.pylori infection leads to 
a chronically inflamed state of the gastric milieu. This is found to be a significant 
risk factor contributing to the development of adenocarcinoma. (75, 76) 
In the year 1994, the International agency for research on Cancer working 
group WHO defined H.pylori as a grade–I or definite human carcinogen. (77) 
Study by Xue FB et al states that “H. pylori infection pre-exists in gastric 
carcinoma and precancerous lesions, the results of Meta analysis present a strong 
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evidence to support the conclusion that H. pylori infection is a risk factor for 
gastric carcinoma”. (10) Eslick GD et al found that there is a 2 fold increase in risk 
of gastric carcinoma among H. pylori infected patients. (11)  
Gastric Malt Lymphoma:  
Gastric lymphoma is the proliferation of mucosa associated monoclonal B 
lymphocytes. There is a strong correlation between prevalence of gastric MALT-
oma and H.pylori colonization. In-vitro studies on the proliferation of cells derived 
from these lymphomas show that, this change is dependent on H.pylori specific T 
cells and their products and not due to the bacteria themselves. (78) Eradication of 
H.pylori results in regression of this tumor. Gastric MALT lymphoma is the only 
known malignancy which can be prevented by elimination of H.pylori infection.  
(79, 80) 
Though majority of MALT lymphoma patients are positive for H. pylori 
infection, only less than 1% of those who tested positive for H. pylori developed 
MALT lymphoma (81). The eradication of the bacteria in MALT patients can lead 
to complete remission in 60%–80% of patients with stage 1 low-grade gastric 
MALT lymphoma. (82,83) In Uemura et al study gastric cancer was seen in 
approximately 3% of infected patients, compared to none of the uninfected 
patients. This study also supported the fact that eradication of infection 
would decrease the risk of gastric cancer in infected individuals without 
premalignant lesions. (64) Taken together, these studies support an unequivocal role 
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for Helicobacter pylori in the development of gastric carcinoma and that the anti-
H. pylori therapy will be an effective means of prevention. 
 
DIAGNOSIS: 
Various tests are available to diagnose H.pylori infection. They are broadly 
categorized into  
1. Invasive tests  (Direct) 
2. Non invasive tests  (Indirect) 
The invasive tests are based on Gastric Biopsy. Direct microscopy with 
appropriate staining, Rapid urease tests, PCR, Immuno histochemistry are some of 
the methods used in diagnosing the infection in tissue sample. 
Non invasive tests obviate the need for biopsy. It comprises of serology, urea 
breath test and stool antigen test. Due to the patchy distribution of this bacteria in 
the stomach, biopsy based tests have a slight disadvantage of missing the 
diagnosis of infection as opposed to non invasive methods. But the endoscopy 
allows the assessment of disease state and the need for treatment. (20) 
INVASIVE TESTS: 
Endoscopy must be performed at least 4 weeks after the last treatment with 
antibiotics and proton pump inhibitor. Biopsy must be taken from the antrum and 
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body of stomach. The sample must be processed immediately or can be stored at 
4oC for one hour. 
1. Rapid urease test: 
H.pylori has a very high urease activity that can be utilized for diagnosis of 
infection. This test was first described by Mc Nulty and Wise by using 
Christensen’s urea broth incubated up to 24 hours. (84) Later several modifications 
were made to make the test rapid. Currently several commercial preparations like 
CLO test, Stuart’s urease test broth, Pylori-tek are available which are designed to 
give results in few minutes. Positive predictive value of these tests is high. At least 
104 organisms are required to give a positive result. Sensitivity of the test is 85-
95% and specificity is 90-95%. (85) 
2. Microscopy:  
Several staining methods are available to stain the tissue sections for 
demonstrating H.pylori. Advantage of H & E stain is that it allows studying the 
nature of the disease in the gastric tissues as well. This could demonstrate the 
various diseases associate with H.pylori. 
Some of them are Modified Giemsa stain, Hematoxylin and eosin stain, 
Gimenez, Warthin –starry stain,  Leifson, Acridine orange. Methylene blue 
staining can also be used. Among these modified Giemsa stain is simple, cheap 
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and less labor intensive. (18) Immuno-histochemistry and fluorescence in situ 
hybridization are few other sensitive methods to demonstrate H.pylori in tissue. (86) 
3. Culture: 
 Culture is the most specific method (100%) to establish diagnosis.(87)  But 
its sensitivity depends on the effective transport of samples, skill of the laboratory 
personel and the sophistications available in lab. Culture is done on biopsy sample 
from antrum and corpus of stomach, but antral lesser curvature sample yields the 
best result. 
Specimens must be plated on both selective and non selective media. The 
sensitivity of culture varies from 80-95%. Samples are incubated under 
microaerophilic condition at 37oC under humid conditions. Colonies are visible 
after 3-5 days of incubation. They are small, translucent, dome shaped more than 
3mm. On Gram stain- Gram negative curved rods, that tests positive for urease, 
catalase and oxidase is considered to be H.pylori. (19) 
Advantage of culture is that it allows for performance of antibiotic 
sensitivity profile on the isolated bacteria. But the major disadvantage is its time 
consumption and requirement of expertise to culture making this mostly a research 
methodology rather than a regular diagnostic procedure. Delay in transport and 
inefficient handling of sample can have an adverse impact on recovery of this 
organism by culture. 
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4. Molecular methods: 
Molecular tests are performed on samples like gastric biopsy and gastric 
mucosal brushing. (88) Several molecular methods based on hybridization and 
amplification (PCR, LAMP) have been developed. They are useful in diagnosis 
and post treatment evaluation. Sensitivity and specificity of PCR are 95% and 
100% respectively.(89) Apart from diagnosis, PCR also allows for detection of 
diversity, virulence and resistance pattern. Primers for detection of housekeeping 
genes involved in urease production are used for identification (Ure A, B, C gene). 
glmM gene (ureC) is considered most specific for H.pylori detection. (90) RFLP 
analysis can be used to separate isolates based on the restriction fragment sizes. 
NON INVASIVE TESTS: 
1. Urea Breath test: 
Urease activity can be detected by radioactive carbon 13C and 14C urea 
breath test. The sensitivity and specificity ranges from 90-100%. (91) However 
this test is not well approved for routine diagnosis because of risk of radiation 
exposure and requirement of expensive equipments. 
2. Stool antigen assay: 
It is a valuable, non invasive alternative to UBT. H.pylori is constantly shed 
in stool along with the gastro-intestinal epithelial cells. Detection of shed 
antigen using anti-H.pylori antibody based on ELISA, Immuno-
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chromatography, Lateral flow assay, etc is available. (92) Usage of monoclonal 
antibodies is found to be better than polyclonal antibody based detection. ICT 
is cheap and field based method. It can be used in smaller laboratories that do 
not have equipment for performing EIA. Immuno Card STAT HpSA has been 
reported to have sensitivity of 96% and specificity of 90%. (93) 
3. Antibody detection (serology): 
This method is simple, cost effective and has better reproducibility. Yet the 
method is not specific enough to be used as a screening procedure in the 
endemic population. IgM develops soon after patient gets infected followed by 
IgG and IgA. Various methods for detection of these antibodies are 
complement fixation, agglutination, immunoblot and ELISA. The antigens for 
ELISA are whole cell lysate, acid glycine extract and high molecular weight 
associated recombinant proteins of UreB, VacA and CagA. 
In Immunoblot assay the above said proteins are immobilized on a 
nitrocellulose membrane and used for detection of IgG in patient’s serum. The 
sensitivity and specificity of the test is 90% compared to that of ELISA. (94) 
4. String test: 
Patients are asked to swallow an absorbent string on an empty stomach and 
it is allowed to stand in stomach for 15-30 minutes. It is then withdrawn and 
the distal end is used for testing urease, culture and PCR. This is a non invasive 
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method for collection of sample for more specific tests. The sensitivity of this 
method of collection is good for PCR compared to culture. (95, 96) 
 
EPIDEMIOLOGY: 
Although Helicobacter pylori infection is found in more than 50% of the 
world population, there is an increased prevalence in developing countries rather 
than the developed ones. (97) Maximum prevalence of H.pylori infection of more 
than 90% is seen in the African and few of the Asian countries. Prevalence in 
India is estimated to be 88% in adults by World Gastroenterology Organization in 
2010. (98) Its high in South India compared to Northern states. 
There is a significant variation in prevalence between countries and also in 
different regions within the same country. H.pylori sero-positivity rate increases 
progressively with age, reflecting a cohort phenomenon. Most of the infections 
occur during childhood and there is a significant reduction in incidence with 
improving hygienic practices. Studies show that the incidence of H.pylori 
infection is 2.7-36% in children as opposed to 0.4% in adults. (90)  
Person to person transmission is the most likely mode. This occurs either 
by the oral-oral route or the fecal-oral route. This would explain the clustering of 
H. pylori infection within families and higher incidence of infection among 
institutionalized children and adults. Fecal contamination of the drinking water is 
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another possible mode of spread of infection. The only proven mode of iatrogenic 
transmission of H. pylori is following endoscopy. (97) 
Adequate nutritional status like consumption of fruits rich in vitamin C and 
vegetables appears to protect against infection with Helicobacter pylori. Risk 
factors of infection include inadequate sanitation practices, crowded or high-
density living conditions, low social class and consumption of food prepared under 
poor hygiene. 
 
TREATMENT:  
Indications for treatment of Helicobacter pylori infection are (99) 
1. Past or present duodenal or gastric ulcer patients, with or without 
complication. 
2. Post-resection of gastric cancer 
3. Gastric (MALT) lymphoma 
4. Atrophic gastritis 
5. Dyspepsia 
6. Patients who have first-degree relatives with gastric cancer 
Multidrug regimens are commonly used. Triple therapy or quadruple 
combinations are the most successful ones. Triple-therapy with PPI + two 
antibiotics is most accepted worldwide. Here the patients are treated for 7-14 days. 
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Antibiotics normally chosen are amoxicillin and Clarithromycin or metronidazole 
and Clarithromycin. Failure to eradicate the infection, with this method, is 
surfacing in recent years due to Clarithromycin resistance. 
In Quadruple therapy bismuth salicylate is added to PPI with amoxicillin + 
Clarithromycin or metronidazole + tetracycline and administered for 10-14 days. It 
is cheaper than triple therapy.  
Proton pump inhibitors are added to increase the pH in stomach, for the better 
action of the other drugs in the regimen. (100)It also alleviates the symptoms of 
acidity.  
All the drugs used in these therapies have a high incidence of adverse effects 
like nausea, metallic taste leading to discontinuation of treatment adding to the 
failure rate. 
Eradication is defined as negative test for H.pylori by urea breath test or stool 
antigen test or check endoscopy, at least 28 days after the end of antimicrobial 
therapy. 
Apart from the above mentioned, other First-line therapies (101) are  
1. Concomitant therapy- PPI + clarithromycin + amoxicillin and 
metronidazole  for 7–10 days 
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2. Hybrid therapy - 7-day dual therapy with a PPI +  amoxicillin  followed 
by a 7-day quadruple therapy with a PPI  + amoxicillin + 
Clarithromycin + metronidazole  
3. Sequential therapy - 5day dual therapy with a PPI and amoxicillin 
followed by a 5-day triple therapy with a PPI+ clarithromycin  and 
metronidazole 
 
DRUG RESISTANCE: 
Like any other bacteria, H pylori is also developing drug resistance and the 
prevalence of resistant strains is increasing at an alarming rate due to the 
widespread use of antibiotics like Macrolides , Quinolones and Metronidazole. 
Systemic review of studies done from 2006 - 2009, by De Francesco V et al 
concluded that the antibiotic resistance rates of Helicobacter pylori were 26.7% 
for metronidazole, 17.2% for clarithromycin, 16.2% for levofloxacin, 11.2% for 
amoxycillin, 5.9% for tetracycline, 1.4% for rifabutin and 9.6% for multiple 
antibiotics. Prevalence of resistance to clarithromycin, metronidazole, and 
levofloxacin has increased in Asia, America and Africa compared to Europe. 
Tetracycline resistance is less than <3% in all countries except Africa (43.9%). (14) 
Study conducted by Thyagarajan et al showed that the H. pylori resistance 
rate was 77.9% to metronidazole, 32.8% to amoxycillin and 44.7% to 
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clarithromycin. (15) Multiple resistances were seen in 43.2% isolates. Patterns with 
two, three and four drug resistance were seen in 13.2, 32 and 2.56% samples 
respectively to the following drugs-  metronidazole, Clarithromycin and 
amoxycillin. Metronidazole resistance was high in Lucknow (68%), Chennai 
(88.2%) and Hyderabad (100%) and moderate in Chandigarh (38.2%) and Delhi 
(37.5%). Ciprofloxacin and tetracycline had the least resistance (1.0 to 4%) (48). 
H.pylori shows a marked allelic diversity due to their higher mutation rate 
compared to many other bacteria due to an incomplete DNA mismatch repair 
system (mutS1/MutL/mutH) and lack of enzymes involved in base excision repair. 
This may be one of the reasons for its high-level resistance to commonly used 
antibiotics such as clarithromycin. (102) 
 The rate of Clarithromycin resistance, globally, varies widely from 49% in 
Spain to 1% in The Netherlands. In places where Clarithromycin resistance is 
<10%, a standard triple therapy can be employed to achieve an eradication rate of 
>90%. On the other hand this standard therapy should be avoided in areas with 
clarithromycin resistance ≥20% (ie, Turkey, Spain, China, Alaska and Japan).  
Performance of culture and Antibiotic susceptibility testing guided choice of 
therapy is a better method to treat patients who failed with first line eradication 
methods. 
 38 
In drug resistant patients, second line therapies with Fluoroquinolones are 
used in place of Clarithromycin. Levofloxacin and moxifloxacin are the 
commonly chosen ones. (101) 
 
PREVENTION AND CONTROL: 
Spread of infection within the family members can be controlled by 
educating the people about the hygienic practices and need for diagnosis and 
treatment of infected patients. Practices of good hand hygiene, eating properly 
cooked food and consuming safe drinking water can reduce the infection rate to 
significant extent. Strict implementation of sanitary measures helps to avoid 
infection in community. At present there is no vaccine available to prevent 
H.pylori infection. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS & METHODS 
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This prospective observational study was conducted in the Department of 
Microbiology, PSGIMS&R after obtaining institutional Human ethical 
committee’s approval. 
STUDY PERIOD:  May 2014- June 2015. 
SAMPLE SIZE: 
 Gastric biopsy samples were collected from 165 patients with gastro 
duodenal diseases undergoing Upper GI Endoscopy in Gastroenterology 
department in PSG Hospitals, Coimbatore. 
SAMPLE SIZE JUSTIFICATION:  
Formula used: n= t2 x p (1-p)/m2 
Where; 
n=required sample size 
t=confidence level at 95% (standard value of 1.96) 
p=estimated prevalence of H pylori 
m=margin of error at 5% (standard value of 0.05) 
Estimated prevalence from hospital statistics (p)=0.88 
n=1.96X1.96X 0.88(1-0.88)/0.05X0.05 
n=165 (162) 
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INCLUSION CRITERIA: 
Patients with symptoms suggestive of following conditions were included in the 
study 
1. Non Ulcer Dyspepsia (NUD) 
2. Peptic Ulcer Disease (PUD) 
3. Gastric carcinomas 
4. MALT lymphoma 
EXCLUSION CRITERIA: 
Patients who had received antibiotics within the past 1 month period and anti 
secretory drugs within the past 2 weeks prior to endoscopy were excluded 
CONSENT: 
Written Informed consent to be enrolled in the study was obtained from patients 
before performing Endoscopy.  
ETHICAL CLEARANCE: 
This prospective study was approved by the Ethical Committee of PSG IMS&R 
STATISTICAL ANALYSIS: 
Statistical analysis was performed using SPSS software (Statistical Product and 
Services Solutions, version 17, SPSS Inc, Chicago, Il, USA) to analyze data. 
Association between gastric lesions and genotypes was tested independently using 
Pearson’s chi2 test and Fischers exact test. All Chi2 test and Fischers exact test 
results with P-values less than 0.05 were considered statistically significant 
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Patients attending Gastroenterology OPD with following symptoms 
suggestive of  non ulcer dyspepsia, PUD, Gastric carcinoma 
Written consent obtained from patient 
for inclusion in the study 
Upper GI endoscopy performed 
Three biopsy tissues transported to 
microbiology lab in Brucella broth 
Endoscopy finding noted  
 
PCR for glmM Rapid urease test Culture in Brucella blood 
Antibiotic  susceptibility testing 
for Clarithromycin & 
Amoxicillin 
CagA and VacA variant 
detection in Helicobacter 
pylori positives 
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ENDOSCOPY PROCEDURE: 
  Patients were instructed to fast for a minimum of 12 hours before 
endoscopy. The Fibreoptic gastroduodenoscope was rinsed thoroughly with water 
and disinfected by placing in a solution of 2% gluteraldehyde for 20 minutes. The 
endoscope was rinsed in sterile physiological saline just before the procedure. 
Patient’s throat was sprayed with lignocaine spray to reduce gagging and they 
were made to lie down in left lateral position comfortably. The end of the 
endoscope was lubricated with lignocaine jelly before inserting into the mouth. 
The patient was asked to swallow until the scope reached the esophagus. Internal 
structure of stomach and duodenum were studied for ulcers, erosion, 
inflammation, discoloration and abnormal growth. Findings were noted and 3 
biopsy samples were taken preferably from the site of lesion and gastric antrum 
using biopsy forceps.  
Three biopsy bits were transported in Brucella Broth to microbiology laboratory 
within an hour of collection. One bit was used for performing each of the below 
mentioned tests. 
1. Rapid urease test 
2. Culture 
3. Polymerase Chain Reaction 
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RAPID UREASE TEST:  
First bit was used for Rapid urease testing. Freshly prepared rapid urease 
broth was used. To a 100 ml of sterile distilled water, 20 grams of urea was 
weighed and added with decreased chances of contamination. pH of this broth was 
adjusted to 5 with 1N HCl and confirmed with litmus paper. Phenol red 0.002gm 
(indicator) was added and filtered in membrane filter and dispensed as 1ml broths, 
in autoclaved sterile eppendorf tubes.(103) The final color of the medium was 
yellowish brown.  The biopsy bit was added to this broth as soon as possible and 
the tubes were incubated at 37oC. An uninoculated tube was kept as negative 
control. Positives were recorded when the tissue sample turned pink within 20 
minutes. The entire 1 ml broth turned pink in next few hours. Few samples gave 
weak positive result which appeared only after incubation for 4 hours.  
H pylori produces large amount of urease enzyme which splits urea into 
ammonia and carbon dioxide. This test detects the increase in pH of the medium 
due to ammonia using an indicator (phenol red). Change in color from yellow to 
reddish pink indicates positive. 
FIGURE 1: IN-HOUSE RAPID UREASE TEST 
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POLYMERASE CHAIN REACTION: 
 Second bit was stored at -80oC in 70% ethanol under sterile condition for 
Extraction and PCR. Extraction was done using QIAmp DNA MINI extraction kit 
(QIAGEN). Procedure given by the manufacturer was followed for extraction. 
Principle of PCR: 
 PCR is based on the principle of exponential amplification of a desired 
fragment of DNA, based on DNA replicative mechanism. It involves denaturation 
of double stranded DNA followed by annealing of primers for the desired 
amplicon and extension of primer. 
Instruments and materials: 
 Vortex mixer 
Refrigerated micro centrifuge –Legend Micro 21R 
Thermo cycler  
Dry bath - Thermocon DB900 
Micropipettes 1000 µl, 100 µl and 200 µl 
Barrier tips 1000 µl and 200 µl 
 
Components of QIAamp DNA MINI kit: 
Tissue lysis buffer (ATL) 
Lysis buffer (AL) 
Proteinase K 
Wash buffer I & II 
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Elution buffer 
Spin columns 
2 ml collection tubes 
The kit can be stored at room temperature (15-25oC)  
 
Extraction Procedure: 
Pre-extraction steps 
25ml of absolute ethanol was added to wash buffer 1(AW1) 
30ml of absolute ethanol was added to wash buffer 2(AW2) 
Dry baths were set at 56oC and 70oC 
Extraction steps 
 In a sterile 1.5 ml centrifuge tube, gastric biopsy tissue was taken and 180µl 
of tissue lysis buffer and 80 µl of phosphate buffer saline was added and the 
tissue was ground to make a homogenous mixer. 
 To this 100 µl of ATL and 20 µl of proteinase K was added. 
 Mixer was vortexed and incubated at 56oC in dry bath for 2-3 hours with 
intermittent vortex until the pellet was completely lysed. 
 Tube was removed from dry bath and 200 µl of AL was added. 
 The mixture was vortexed well and incubated at 70oC for 10 minutes in dry 
bath. 
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 The tube was removed from the dry bath. To this 200 µl of absolute ethanol 
was added and vortexed.  
 The lysate was transferred to the upper reservoir of a labeled Spin column 
tube without wetting the rim. The tube was centrifuged at 8000 rpm for 1 
minute in cold centrifuge. 
 Collection tube with contents was discarded. Spin column was transferred 
to a new 2ml collection tube. To this 500 µl of AW1 was added and 
centrifuged at 8000 rpm for 1 minute. 
 The above step was repeated with 500 µl of AW2 and centrifuged at 14000 
rpm for 3 minutes. 
 Spin column tube is transferred to a new 2ml collection tube and 
centrifuged at full speed 14800 rpm for 1 minute for final filtration. 
 Spin column tube was placed in a new sterile 1.5ml eppendorf tube for 
elution of DNA. To this 200 µl of elution buffer was added and held at 
room temperature for 5 minutes. Centrifuged at 8000 rpm for 1 minute and 
eluted material is store at 4oC for PCR.  
Cells are lysed during the incubation period with proteinase K in the presence 
of chaotropic salts and detergents in the lysis buffers. Once the digest is 
centrifuged, the DNA in it binds to the silica in the spin column tubes. On 
subsequent washing steps the impurities like proteins and polysaccharides are 
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removed. Finally a low salt elutes like Tris is added to elute the DNA bound to the 
silica. 
PCR FOR THE DETECTION Of glmM GENES:  
                PCR was performed for 165 tissue samples for detection of glmM gene 
which is one of the house keeping genes of Helicobacter pylori. The primers used 
were obtained from Sigma Aldrich, Mumbai, which were based on reference 
article from a previous study. The primers used were as follows. 
Gene Primer Sequence(5′-3′) Amplicon size (bp) Reference 
glmM  F- AAGCTTTTAGGGGTGTTAGGGGTTT 
R- CGCAATGCTTCAATTCTAAATCTTG 
136 104 
 
 
Reaction mixture: 
                Each single reaction mixture (25µl) contained 4 µl of DNA suspension, 
12.5 µL of Master Mix (10mM dNTPs, 1 U Taq DNA polymerase, 25mM MgCl2 
and 2.5 µl of 10 x Taq buffer ) and 1µM of each primer (Sigma- Aldrich, 
Mumbai). The remaining volume was adjusted with PCR grade water.  
Positive and negative controls were setup with each batch of tests run. 
Polymerase chain reaction: 
                     The PCR was performed by conventional method using a Eppendorf 
thermal-cycler, under the following conditions.  
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Initial denaturation at 95°C for 10 minutes, 35 cycles of 95°C for 30 
seconds, annealing temperature 60oC for 45 seconds and extension at 72°C for 1 
minute  and a final elongation at 72°C for 5 minutes 
              The products after amplification are stored at -20°C until they were 
subjected to agarose gel electrophoresis. 
 
Agarose gel electrophoresis: 
               The amplified product is visualized by use of agarose gel electrophoresis. 
The agarose gel was prepared to a ratio of 1% by adding agarose gel powder with 
Tris Borate EDTA (TBE) buffer. This mixture was heated in microwave till it 
becomes a clear solution and followed by the addition of Ethidium bromide was 
added to visualize the amplified DNA under UV light. The mixture was allowed to 
set in an electrophoresis tank with comb in place. 
             A 100 base pair ladder was used as the molecular marker to measure the 
size of the amplified product from the PCR in the first well and the rest of the 
wells had 5µl of the amplified product along with 3 µl of the loading dye from 
Sigma Aldrich was used to visually see the movement of the product. The gel 
electrophoresis was performed by placing the gel in an electrophoresis tank 
containing Tris Borate EDTA (TBE) buffer at 100 volts for 40 minutes.   
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Interpretation: 
The ethidium bromide was used to stain the amplified DNA for 
visualization under UV illumination. Then images of the gel were captured by Gel 
doc. Sixty one samples were found to be positive for glmM gene having 136bp, 
confirmed by the 100bp ladder that was used for this purpose. 
  
Figure 2: Gel Electrophoresis picture showing glmM gene 
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PCR FOR cagA And VARIANTS OF vacA GENES: 
                PCR for analysis of VacA s1/s2 and VacA m1/m2 mosaic structure 
analysis and the presence of cagA gene was performed for the 61 isolates which 
were positive for glmM gene. The primers used were obtained from Sigma 
Aldrich, Mumbai, which were based on reference article from a previous study. 
The primers used were as follows 
Genes Primer name and Sequence(5′-3′) Amplicon 
size (bp) 
Reference 
VacA 
s1/s2 
VAI-F    ATGGAAATACAACAAACACAC 
VAI-R   CTGCTTGAATGCGCCAAA   
259/286 
 
8, 64 
VacA 
m1/m2 
VAG-F    CAATCTGTCCAATCAAGCGAG                          
VAG-R    GCGTCAAAATAATTCCAAGG   
567/642 28, 105 
cagA       cag5c-F   GTTGATAACGCTGTCGCTTC 
cag3c-R GGGTTGTATGATATTTTCCAT AA  
350 8 
                
 Each single reaction mixture (25µl) contained 4 µl of DNA suspension, 
12.5 µL of Master Mix (10mM dNTPs, 1 U Taq DNA polymerase, 25mM MgCl2 
and 2.5 µl of 10 x Taq buffer ) and 25pmol of each primer for VacA genes and 
10pmol of each primer for cagA gene (Sigma- Aldrich, Mumbai). The remaining 
 
 
51 
volume was adjusted with PCR grade water. Positive and negative controls were 
setup with each batch of tests run. 
Polymerase chain reaction: 
                     The PCR was performed by conventional method using a thermo-
cycler, under the following conditions, which were same for all the four genes. 
Initial denaturation at 94°C for 3 minutes, 35 cycles of 94°C for 1 minute, 
annealing temperature of 55oC for 1 minute and extension at 72°C for 1 minute, 
and a final elongation at 72°C for 10 minutes 
           The amplified products were stored at -20°C until they were subjected to 
agarose gel electrophoresis as described above 
 
Interpretation: 
All glmM gene positivity indicates that the patients harbor Helicobacter 
pylori in their gastric tissue. Strain was determined to be positive or negative for 
cagA gene based on the presence or absence of specified 136bp amplicon 
respectively.  
In VacA s region analysis, amplicon size of 259 and 286 indicates vacAs1 and s2 
respectively. Similarly amplicon size of 567 and 642 base pairs indicates VacAm1 
and m2 respectively. A single strain harbors any one of the variant in each gene 
eg. VacA s1/m1, VacA s1/m2, etc.  
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FIGURE 3: GEL ELECTROPHORESIS PICTURE SHOWING CagA 
GENE 
FIGURE 4: GEL ELECTROPHORESIS PICTURE SHOWING VacA 
s1/s2 GENE
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FIGURE 5: GEL ELECTROPHORESIS PICTURE SHOWING VacA 
m1/m2 GENE 
 
FIGURE 6: MATERIALS REQUIRED FOR MOLECULAR STUDY 
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CULTURE: 
The biopsy specimen collected in Brucella broth was processed within 2-3 
hours from the time of collection. The biopsy tissue was minced to pieces using a 
sterile no.22 scalpel blade on a sterile glass slide. The minced tissue was 
inoculated to a freshly prepared selective medium, Brucella chocolate agar (106, 107) 
supplemented with vancomycin, Polymyxin B and amphotericin B. This antibiotic 
combination was chosen based on the common contaminants encountered during 
processing. Prepared plates were stored in sterile box at 4oC for not more than a 
week. Culture plates were incubated under microaerophilic atmosphere 10% CO2, 
5% O2, 85% N2 at 37oC using Anoxomat system. The incubation jar was opened 
on 3rd, 5th, 7th and 10th day and checked for growth. Plates which had no growth 
were discarded after 10th day. 
Helicobacter pylori grew on plate as tiny (0.5-1 mm), moist, convex and 
watery colonies (translucent). Identification was confirmed by Gram stain, 
catalase, oxidase and urease tests. (Fig 7) 
Single colony was emulsified in a drop of saline on a clean glass slide. The 
smear was air dried and fixed with a few drops of methanol. On Gram stain‘s’ 
shaped or seagull shaped Gram negative spirals were seen. (Fig 8) 
A colony was picked with sterile glass rod and dipped into 3% hydrogen peroxide 
solution in a test tube. Appearance of prompt bubbling indicates a positive 
reaction. H.pylori is strongly catalase positive. (Fig 9) 
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A suspected colony was smeared on to a dry filter paper impregnated with 
Tetramethyl para-phenylene diamine dihydrochloride. H.pylori shows change of 
colour from white to purple within 10 seconds indicating oxidase positivity. (Fig 
9) 
When a few colonies were streaked on the slant of Christensen’s urease 
agar, a rapid color change from yellow to pink occurred, demonstrating the 
presence of urease and indicating the presence of H pylori. (Fig 9) 
The growth was stored in broth made of equal parts of BHIB with 15% 
glycerol and skimmed milk at -80oC. 
FIGURE 7: GROWTH OF H.pylori IN CHOCOLATED BRUCELLA AGAR 
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FIGURE 8: GRAM STAIN IMAGE OF H.pylori 
 
 
FIGURE 9: BIOCHEMICAL TEST FOR IDENTIFICATION OF H.pylori 
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ANTIBIOTIC SUSCEPTIBILITY TESTING: 
Isolates were tested for Clarithromycin and Amoxicillin. Isolated organism 
was sub cultured on antibiotic free Brucella chocolate agar. On an average, 
organism took 3 days to grow on sub culture. The growth was emulsified in 
Brucella broth and matched to Mc Farland standard of 4. Lawn culture was made 
in a Brucella chocolate agar with sterile cotton swab. E-strip (Biomerieux) was 
placed at the center with a sterile applicator and the plates were incubated in 
micro-aerophilic atmosphere at 37oC for 72 hours. (108) Reading on the strip at the 
point of intersection of the growth was taken as MIC of that isolate. (Fig 10) 
 
FIGURE 10: E-TEST METHOD OF ANTIBIOTIC SUSCEPTIBILITY 
TESTING 
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MIC CUT OFF FOR DETERMINATION OF ANTIMICROBIAL 
SUSCEPTIBILITY IS AS FOLLOWS 
 
 
ANTIBIOTICS 
 
SUSCEPTIBLE 
 
INTERMEDIATE 
 
RESISTANT 
 
REFERENCE 
 
CLARITHROMYCIN 
 
≤0.25 
 
0.5 
 
≥1.0 
 
109 
 
AMOXICILLIN 
 
≤0.25 
 
0.5 
 
≥1.0 
 
110 
 
 
ENDOSCOPY FINDINGS: 
 Upper GI endoscopy findings were noted down in endoscopy unit 
following the procedure as normal, Gastritis, Gastro duodenitis, Gastric ulcer, 
Duodenal Ulcer, CA Stomach and others. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS & ANALYSIS 
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Out of the 165, 107 (64.85%) were male and 58 (35.15%) were female. 
This shows the increased prevalence of gastro duodenal disease among male 
compared to female. 
 
  
 The selected 165 patients were analyzed based on their age. Of the 165, 
maximum number of cases were under the age group of 51-60 years, 43 (26%) 
followed by 34 (20.6%) falling under 31-40 years. The study population falling 
under the age groups of 41-50 and 61-70 years were 16% each. The rest were 
below 30 years and above 70 years. The mean age of the cases was 49 years.( Fig -
12) 
64.85%
35.15%
Figure 11: Sexwise distribution of study group
Male
Female
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FIGURE 12: GRAPH OF AGE WISE DISTRIBUTION OF STUDY GROUP 
 
 The above graph shows that majority of the patients undergoing 
Upper GI endoscopy for gastro duodenal diseases fall under the age group of 30-
70 years. 
TABLE 1: DISTRIBUTION OF CASES AMONG THE STUDY GROUP 
ENDOSCOPIC FINDINGS NO. OF CASES (%) 
Gastritis 101(61.2) 
Gastric ulcer 14(8.4) 
Duodenal ulcer 3(1.8) 
Gastroduodenitis 11(6.7) 
Carcinomatous growth 3(1.8) 
Normal study 23(14) 
Others 10(6.1) 
TOTAL  165(100%) 
7
15
34
27
43
26
13
11-20 yrs 21-30yrs 31- 40yrs 41-50yrs 51- 60yrs 61- 70yrs 71- 80yrs
No of patients 
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 The Table 1 shows that among the 165 dyspeptic patients, endoscopic 
finding suggestive of gastritis  (antral, fundal, diffuse or erosive gastritis) was seen 
in 101 (61.2%) patients, gastric ulcer and duodenal ulcer were seen in 14 (8.4%) 
and 3 (1.8%) patients respectively and Gastroduodenitis was seen in 11 (6.7%) 
cases.  Three patients had growth in stomach which was later identified as gastric 
carcinoma. Fourteen percent of patients had normal study. Six percent of patients 
had other conditions like polyps, Barrett’s esophagus, diverticula, Tropical sprue, 
etc 
FIGURE 13: CHART SHOWING DISTRIBUTION OF STUDY 
POPULATION WITH RESPECT ENDOSCOPIC FINDINGS 
 
Gastritis, 61.2
Gastroduodenit
is
6.7
Gastric 
ulcer, 8.4
Duodenal 
ulcer, 1.8
CA 
stomach, 1.8
Other 
findings, 6.1
Normal 
study, 14
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FIGURE 14: PERCENTAGE OF POSITIVITY FOR H.pylori BY VARIOUS 
METHODS 
 
 
 Out of 165 samples tested, 67 (40.6%) were positive by rapid urease 
test, 52 (31.5%) by culture and 61 (37%) by PCR. 
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TABLE 2: POSITIVITY OF VARIOUS TESTS AMONG VARIOUS 
GASTRODUODENAL DISEASES 
 
 
ENDOSCOPIC 
DIAGNOSIS 
 
NO. OF 
CASES 
NO. OF POSITIVES BY VARIOUS 
METHODS 
RUT 
N (%) 
Culture 
N (%) 
PCR 
N (%) 
GASTRITIS 101 38 (37.6) 29 (28.7) 35 (34.7) 
GASTRODUODENITIS 11 6 (54.5) 6 (54.5) 6 (54.5) 
GASTRIC ULCER 14 12 (85.7) 10 (71.4) 11 (78.6) 
DUODENAL ULCER 3 3 (100) 3 (100) 3 (100) 
CARCINOMA 
STOMACH 
3 1 (33.3) 0 
 
0 
 
NORMAL STUDY 23 6 (26.1) 4 (17.4) 5 (21.7) 
OTHERS 10 1 (10) 0 1 (10) 
TOTAL 165 67 (40.6) 52 (31.5) 61 (37) 
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TABLE 3: ASSOCIATION OF ABNORMAL ENDOSCOPIC FINDING AMONG POSITIVE AND NEGATIVE 
CASES 
 
H.pylori 
infection* 
 
ENDOSCOPIC FINDINGS 
 
P value 
Gastritis 
N (%) 
Gastroduo
denitis 
N (%) 
Gastric 
Ulcer 
N (%) 
Duodenal 
Ulcer 
N (%) 
CA 
stomach 
N(%) 
Others 
N (%) 
Normal 
N (%) 
Positive 35(34.7) 6(54.5) 11(78.6) 3(100) 0(0) 1(10) 5(21.7)  
<0.001 Negative 66(65.3) 5(45.5) 3(21.4) 0(0) 3(100) 9(90) 18(18.3) 
*As per PCR for glmM gene  
 Table-3 shows that there was a significant statistical association (p< 0.001) between the abnormal endoscopic finding 
and H.pylori infection.  
 Results of the association between the individual endoscopic findings and H.pylori infection is shown in the next 
table 
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TABLE 4: STATISTICAL ANALYSIS OF THE ASSOCIATION OF 
H.pylori INFECTION WITH ENDOSCOPIC FINDING 
ENDOSCOPIC 
FINDINGS 
NO. OF CASES H.pylori POSITIVE 
CASES*(%) 
P Value 
Gastritis 101 35(34.7) 0.232 
Gastroduodenitis 11 6(54.5) 0.114 
Gastric ulcer 14 11(78.6) 0.001 
Duodenal ulcer 3 3(100) 0.022 
Carcinomatous 
growth 
3 0(0) 1.000 
Others 10 1(10) 0.640 
Normal study 23 5(21.7)  
TOTAL 165 61(37)  
*H.pylori positive by PCR  
  Among the 101 gastritis patients 34.7% (35) were positive for 
H.pylori infection by PCR. Among gastric and duodenal ulcer patients 78.6% and 
100% were found infected with H.pylori. 6 (54.5%) out of 11 Gastroduodenitis 
patients had H.pylori infection. None of the gastric cancer patients had H.pylori 
infection. Among the normal study cases 21.7% were infected with H.pylori. 
 There was a strong association between H.pylori infection and peptic 
ulcer disease compared to Non ulcer dyspepsia and CA stomach (P < 0.001 for 
gastric ulcer and p< 0.05 for duodenal ulcer) 
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TABLE 5: SEX-WISE DISTRIBUTION OF H.pylori POSITIVE CASES: 
SEX NO. OF CASES INCLUDED IN 
THE STUDY 
H.pylori +ve (%) 
MALE 107 44 (72) 
FEMALE 58 17 (28) 
TOTAL 165 61 
 Out of the 61 total positives, 44 (72%) were male patients and 
17(28%) were female cases. This clearly shows that the prevalence of H.pylori 
infection was more common among male patients than female in Coimbatore 
region. 
TABLE 6: AGE-WISE DISTRIBUTION OF H.pylori POSITIVE CASES: 
AGE GROUP IN 
YEARS 
NO. OF CASES 
INCLUDED IN THE 
STUDY 
H.pylori +ve (%) 
11-20 7 5 (8.2) 
21-30 15 5 (8.2) 
31-40 24 9 (14.8) 
41-50 37 14 (22.9) 
51-60 43 13 (21.3) 
61-70 26 10 (16.4) 
71-80 13 5 (8.2) 
TOTAL 165 61 (100) 
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 Out of the 61 PCR positive H.pylori cases, 75.4% were within the 
age group of 31-70 years. Maximum number of cases (14) was seen within age 
group of 41-50 years followed by 51-60 year group (13). 
TABLE 7: COMPARISON OF RAPID UREASE TESTS AGAINST PCR 
 
RUT 
PCR  
POSITIVE NEGATIVE 
POSITIVE 57 10 67 
NEGATIVE 4 94 98 
TOTAL 61 104 165 
Sensitivity of RUT = 57/61 X 100= 93.4% 
Specificity of RUT = 94/104 X 100= 90.4% 
Positive predictive value = 57/67 X 100= 85.1% 
Negative predictive value =94/98 X 100= 96% 
Accuracy =57+94/165 X 100 = 91.51% 
 Table 7, shows that among the 61 patients who had the infection (by 
PCR method), RUT was positive in 57 cases. False negative occurred in 4 cases. 
Sensitivity and specificity of rapid urease test when evaluated against the 
Polymerase Chain Reaction, was 93.4% and 90.4% respectively. Positive 
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predictive value was 85.1% and negative predictive value was 96%. Diagnostic 
accuracy of RUT was 91.51%.  
TABLE 8: COMPARISON OF CULTURE AGAINST PCR 
 
CULTURE 
PCR  
POSITIVE NEGATIVE 
POSITIVE 52 0 52 
NEGATIVE 9 104 113 
TOTAL 61 104 165 
 
Sensitivity of culture = 52/61 X 100= 85.2% 
Specificity of culture = 104/104 X 100= 100% 
Positive predictive value = 52/52 X 100= 100% 
Negative predictive value =104/113 X 100= 92% 
Accuracy = 52+104/165 X 100= 94.54% 
 From the Table 8, sensitivity of culture was 85.2% when evaluated 
against the gold standard test- Polymerase Chain Reaction. Specificity of culture 
was 100%, positive predictive value was 100% and negative predictive value was 
92% when evaluated against Polymerase Chain Reaction. Diagnostic accuracy of 
RUT was 94.54%.  
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FIGURE 15: PERFORMANCE CHARACTERISTICS OF VARIOUS 
DIAGNOSTIC TESTS 
 
  
 Rapid urease test had better sensitivity of 93.4% compared to culture, 
but culture had the highest specificity and a PPV of 100%. Culture had the highest 
positive predictive value while rapid urease test had a better negative predictive 
value. 
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TABLE 9: ASSOCIATION OF cagA with DISEASE STATUS  
 
ENDOSCOPY 
FINDING 
TOTAL 
CASES 
PCR 
POSITIVE 
cagA 
POSITIVE 
P VALUE 
(Fischer’s exact 
test) 
NORMAL 23 5 2  
0.642 DISEASED 142 56 33 
TOTAL 165 61 35 
 
 Though percentage of cagA positivity was higher in patients with 
significant endoscopic finding (58.9%) compared to the normal cases (40%), this 
difference wasn’t found to be statistically significant (p> 0.05). This may be due to 
the less number of normal cases in this study. 
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TABLE 10: PERCENTAGE OF CagA POSITIVITY AMONG INFECTED 
CASES 
ENDOSCOPIC 
FINDINGS 
PCR 
POSITIVE 
CagA +ve (%) P VALUE 
GASTRITIS 35 16(45.7) 1.0 
GASTRODUODENITIS 6 5(83.3) 0.242 
GASTRIC ULCER 11 10(90.9) 0.063 
DUODENAL ULCER 3 2(66.7) 1.0 
OTHERS 1 0(0) 1.0 
CARCINOMA STOMACH 0 0 - 
NORMAL STUDY 5 2(40) - 
TOTAL 61 35(60.6) 0.057 
  
 People with normal findings and patients with carcinoma stomach 
had no cagA positive strains in this study. Percentage of cagA positivity among 
different conditions was 45.7% in gastritis, 83.3% in Gastroduodenitis, 90.9% in 
gastric ulcer and 66.7% in duodenal ulcer. Statistical analysis by Fisher’s exact 
test revealed that there was no significant association between cagA status and any 
of the endoscopic findings (p > 0.05) 
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TABLE 11: CagA AMONG PEPTIC ULCER DISEASE AND NON ULCER 
DYSPEPSIA 
 cagA +ve cagA -ve TOTAL P Value 
(x2) 
NUD 21 (50%) 21 (50%) 42  
0.027 PUD 12 (85%) 2 (14.3%) 14 
TOTAL 33 23 56 
 
 
 Table 11, shows that cagA gene status was distributed equally among 
patients with non ulcer dyspepsia (Gastritis, Gastroduodenitis, Reflux esophagitis) 
whereas cag A was positive in 85% of patients with Peptic ulcer disease (Gastric 
ulcer and Duodenal ulcer). There was a significant association (p< 0.05) between 
cagA positivity and peptic ulcer disease. Odds ratio = 6 with 95% confidence 
interval between 1.19 – 30.1 
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TABLE 12: CORRELATION BETWEEN ENDOSCOPY FINDINGS AND 
vacA SUBTYPE 
ENDOSCOPY 
FINDINGS 
VacA 
s1m1 
N (%) 
VacA 
s1m2 
N (%) 
VacA 
s2m1 
N (%) 
VacA 
s2m2 
N (%) 
P value 
GASTRITIS 12 (34.3) 12 (34.3) 5 (14.3) 6 (17.1) 0.015 
GASTRODUODENITIS 3 (50) 3 (50) 0(0) 0(0) 0.012 
GASTRIC ULCER 7(63.6) 4(36.4) 0(0) 0(0) 0.001 
DUODENAL ULCER 3(100) 0(0) 0(0) 0(0) 0.018 
OTHERS 0(0) 0(0) 0(0) 1(100) 1.000 
CARCINOMA 
STOMACH 
0(0) 0(0) 0(0) 0(0) - 
NORMAL STUDY 0(0) 0(0) 1(20) 4(80) - 
TOTAL 25 
(41%) 
19 
(31%) 
6 (9.8%) 11(18.2%) 0.007 
 
 Among the 35 patients who had gastritis s1m1 and s1m2 subtypes 
predominated with 34.3% each. Gastric ulcer and gastroduodenitis patients shared 
a similar picture where all the strains were either s1m1 or s1m2 subtypes with no 
vacA s2 subtype at all. All 3 Duodenal ulcer patients had vacA s1m1 subtype only. 
Statistical analysis was done using Pearson Chi-square test and there was a 
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significant association between the vacA subtypes and the above mentioned 
endoscopy findings (p <0.01) 
 Table 12 clearly shows that, all 44 vacA s1subtype identified were 
found in patients with pathological findings only where as the s2 subtype was 
found in both normal as well as diseased patients. 
TABLE 13: CORRELATION BETWEEN cagA AND vacA AMONG H 
pylori ISOLATES 
 
       vacA 
 
cagA 
s1m1 s1m2 s2m1 s2m2 s1 s2 P 
value 
cagA+ve 17(68%) 16(84.2%) 1(16.7%) 1(9.1%) 33(75%) 2(11.8%)  
<0.05 cagA-ve 8(32%) 3(15.8%) 5(83.3%) 10(90.9%) 11(25%) 15(88.2%) 
Total 25 19 6 11 44 17 
 
 About 33 (75%) of the 44 vacAs1 isolates were cagA positive, while 
only 2 (11.8%) of the 17 vacAs2 isolates were cagA positive. Occurrence of cagA 
positivity was 33(75%) out of 44 vacAs1 subtype whereas 15 (88.2%) out of 17 s2 
subtype were cagA negative. 
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TABLE 14: STATISTICAL SIGNIFICANCE OF CagA & VacA GENE 
AMONG NUD & PUD PATIENTS 
 
                  Disease 
cagA &  
vacA status 
 
NUD 
 
PUD 
  
P value 
cagA+ve & vacA s1 +ve 21(70%) 12(85.7%) 33  
 
>0.05 
 
 
cagA -ve & vacA s1 +ve 9(30%) 2(14.3%) 11 
 30 14  
 
  
 Among 30 Non ulcer dyspepsia patients with vacAs1 subtype, 21 
(70%) were cagA positive. Among 14 peptic ulcer disease patients with vacAs1 
subtype, 12 (85.7%) were cagA positive. Difference in cagA status had no 
statistically significant association with the disease manifestation in vacA s1 
positive patients. 
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TABLE 15: ANTIBIOTIC SUSCEPTIBILITY OF THE H pylori ISOLATES 
 
 
ANTIBIOTICS 
NO. OF ISOLATES 
SUSCEPTIBLE INTERMEDIATE RESISTANT 
CLARITHROMYCIN 17 (65.38) 7 (27) 2 (7.62) 
AMOXICILLIN 20 (76.9) 2 (7.69) 4 (15.38) 
  
 Of the 52 isolates stored only 26 were revivable for performing AST 
for Clarithromycin and Amoxicillin. Of the 26 isolates, 2 (7.62%) were resistant 
with MIC ≥ 1.0 and 17 (65.38%) were sensitive with MIC ≤ 0.25 to 
Clarithromycin. Percentage of amoxicillin resistance and sensitivity were 15.38% 
(n=4) and 76.9% (n=20) respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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 The present study was aimed at determining the prevalence of 
H.pylori infection in dyspeptic patients, to evaluate the usefulness of Rapid urease 
test, culture and PCR in diagnosing infection, to identify the cagA and vacA gene 
variants and their association with the virulence state and to identify the 
prevalence of Clarithromycin and Amoxicillin resistant strains in our population 
using E test method. 
 Gastritis is the most common cause of dyspepsia in general 
population. Apart from H.pylori infection there are varieties of causes for 
dyspepsia like consumption of drugs especially NSAIDs, alcohol intake, stress, 
food habits, etc. The  endoscopic finding of the patients included in this study also 
showed gastritis to be the most common GI disorder in dyspeptics (61.2%) 
followed by gastroduodenitis (8.4%) and ulcer (3.6%). Similar distribution of 
findings was seen in other studies too. (104, 111)  
 Males (64.85%) suffered more from dyspeptic symptoms compared 
to females (35.15%). Out of the 61 patients who were found to be infected with 
H.pylori infection by PCR, 72% were male and only 28% were female showing an 
increased prevalence of infection in male patients. These results concure with the 
findings of Yoosuf H et, Shanthi et al and Archana et al. (112-114) Several foreign 
studies have results otherwise. Hence sex preponderance may be an unlikely factor 
in H.pylori infection. Increased number of male patients in this study might be one 
of the reasons for increased prevalence of infection seen in them. 
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 Though H.pylori infection rate was said to be high among children, 
our study population had adults predominantly. Hence most of the patients who 
suffered from gastrointestinal disorders and those who had the infection were 
within the age group of 30- 70 years (75.4%). Study by Shanthi et al also showed 
similar distribution of patients. (113) 
 Prevalence is known to vary widely across our country. In the 
current study, the prevalence of H.pylori in gastric mucosa of dyspeptic patients 
visiting OPD for medical attention was 37% in Coimbatore region. This is in 
contrast to the popular belief in the Western world, stating the prevalence to be 70-
90% among Asian population. (90). Similar results were seen with the studies by 
Chattopadhyay et al (50%) from Kolkata, Archana et al (48%) from Bagalkot, 
Tayloor et al (43%) and Mohanprasad et al (22%) from Coimbatore. (8, 114-
116)Higher prevalence of 58-70% was seen in studies from Kurnool, Chennai, 
Amritsar and Chandigarh. (112,113,117-119)  
 In this study the prevalence of Helicobacter pylori infection was 
maximum in patients with duodenal ulcer (100%) and gastric ulcer (78.6%), 
followed by gastroduodenitis (54.5%). H.pylori infection had a significant 
association with peptic ulcer disease rather than non ulcer dyspepsia (p<0.001). 
These findings were in accordance with the studies conducted earlier in India. (112-
115) 
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 On contrary to the studies from Eastern Asia (10-12), all the 3 
carcinoma stomach patients included in this study did not have H.pylori in their 
gastric mucosa. Only 21.7% of the study group with normal endoscopic finding 
had Helicobacter pylori in their gastric mucosa in contrary to the finding by Singh 
et al which quoted the carriage to be 56% in asymptomatic persons. (113) 
 Though culture is considered gold standard for confirming any 
infection, due to the difficulty in cultivation of H.pylori and possibility of growth 
failure due to technical errors, we have considered using PCR as the standard 
method in this study. RUT and culture were compared against PCR. 
  Rapid urease test is cheap and easy to perform in day to day practice. 
Rapid urease test had a better sensitivity (93.4%) and negative predictive value 
(96%) than culture, making it an ideal screening procedure. Study by Chomvarin 
et al and Chattopadhyay et al using a similar preparation of Rapid urease test 
showed the sensitivity 94.1%, 91% and specificity of 94.2 %, 95.6% respectively. 
(8, 120)  
 Study by Refaay et al using conventional buffered urease medium 
gave sensitivity and specificity of 86.7% and 80% respectively.(104) The sensitivity 
of various RUT tests as primary diagnostic tests is high and has been reported to 
vary between approximately 80% and 100% and specificity between 97% and 
99% (121-124). Reason for this wide range was the difference in the formulation of 
the media used for testing. The formulation used in this study was easy to prepare 
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and had a fairly good sensitivity and specificity. This preparation can be used for 
routine testing in our Endoscopy units. 
 RUT of current study showed 10 (15%) false positives and 4 (6%) 
false negatives. False positive results were mostly due to Proteus species found in 
the specimen. False negative may be due to the patchy distribution of this 
bacterium in the gastric mucosa or lesser number of bacteria in the sample. 
Approximately 105 bacteria must be present in the biopsy sample for a positive 
result (125) and anything that reduces the bacterial density may result in false-
negative results (126-128) 
 Isolation rate of the Modified chocolate agar media with Brucella 
agar base used in this study was 85%, which is better than the results obtained 
from other studies. Piccolomini et al had isolation rate of 83% with Modified 
chocolate agar media with Columbia agar base and Refay et al showed isolation 
rate of 62.5% with Columbia blood agar with Dent supplement. (104, 129)  Out of the 
61 H.pylori positive cases 52 were isolated on culture. Seven biopsies had heavy 
contamination with other bacteria (Streptococcus sp, Proteus sp & Pseudomonas 
sp) and Candida species, which might be the reason for failure of H.pylori 
isolation in these samples. Two culture plates had no growth, which could be due 
to decreased bacterial density in those samples. 
Though culture had 100% specificity and 100% positive predictive value, 
there were a significant number of false negatives (14.8%). Culturing of H.pylori 
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is a cumbersome procedure requiring special media and microaerophilic 
atmosphere to grow this organism. It also takes 4-5 days on an average for the 
growth of the organism and its identification. Hence culture can be reserved for 
cases were antibiotic susceptibility testing is warranted.  
 It has been suggested that H.pylori induced gastroduodenal diseases 
varied in severity and manifestations depending on the strain virulence. In this 
study we used glmM gene in gastric biopsy samples for identification of patients 
with Helicobacter pylori infection and positive samples were further analyzed for 
cagA and vacA variant status. Of the 165 samples 61 (37%) were positive for 
glmM gene by PCR.    
On contrary to the Indian studies from Chennai, Calcutta and South east 
Asian countries where the cagA positivity rate was 96% ,92.3%  and 95% 
respectively, current study showed only  60.6% cagA positivity in Coimbatore 
region. However this is in accordance with the western studies (60-70%). (8, 9, 111, 
130) 
 Though cagA positivity was high among gastric ulcer (90.9%) and 
gastroduodenitis (83.3%) patients statistical analysis by Fisher’s exact test found 
no significance (p>0.05) attached to the cagA status and disease manifestation 
when compared to patients with normal endoscopic findings. However there was a 
statistically significant association between presence of cagA gene and peptic ulcer 
disease rather than the non ulcer dyspepsia (p<0.05). Odds ratio was 6 with 95% 
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CI. Samples from peptic ulcer disease (gastric ulcer & duodenal ulcer) cases 
showed 85% cagA positivity while non ulcer dyspepsia (gastritis, 
gastroduodenitis, reflux esophagitis) cases had an equal distribution of cagA status 
among them. This is in accordance to many Indian studies which showed the same 
results. (9)  
Prevalence of vacAs1 variant (72%) was greater compared to s2 variant 
(28%). None of the vacA s1 strains was found in cases with normal endoscopic 
findings. Similar results were found in other studies too. On contrary to other 
studies where s2 strains were never associated with the disease, 12 strains were 
found in patients with gastritis.  
There was a statistically significant correlation between the four vacA 
variants (s1m1, s1m2, s2m1 & s2m2) studied and the disease manifestations 
(p<0.01). All the strains from duodenal ulcer cases were vacAs1m1 type whereas 
gastric ulcer patients had 63.6% and 36.4% of s1m1 and s1m2 respectively. 
VacAs1 subtype was found in all patients with peptic ulcer disease. Similar results 
were found in studies from UK, Western Europe, US, Africa and India. (8, 131- 135) 
  Though few studies showed that multiple vacA strains could colonize the 
stomach of single patient, expressing themselves in PCR (136, 137), none of the 
patients included in this study were colonized with multiple strains.  
The entire normal study group had VacA s2 variant only. None of the ulcer disease 
and gastroduodenitis patients had s2 variants. This clearly shows that vacA s1 is a 
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significant virulence marker and patients harboring s1 strains are more prone to 
develop ulcers.  
Percentage of vacA s1 cagA positive strain was 54.1 in Coimbatore region. 
Studies from Calcutta and Middle East countries showed 68% and 86% prevalence 
respectively. (8,138) 
There was a significant association of cagA with s1 strain rather than s2, but 
when the influence of vacA s1 cagA positive on the diseases manifestations was 
analyzed, there was no significant difference between PUD and NUD. 
Non ulcer dyspepsia patients showed a higher prevalence of vacA s1 compared 
to s2 and this association was significant. VacA m subtype was equally distributed 
among s1 variants and did not have any significance (p> 0.05). This was in 
contrary to the finding from Chennai based study were m2 was found more 
associated with PUD.(9)  
These findings show that the vacA s1 cagA-positive genotype has an important 
role in the clinical outcomes. Hence this genotype can be used to identify patients 
who are at a higher risk for gastroduodenal disease. Patients infected with the 
strain carrying vacA s1 cagA-positive genotype should be given more attention. 
They must be checked for eradication status on completion of antibiotic treatment, 
to prevent the development of PUD in future. 
In this study the resistance to Clarithromycin and Amoxicillin was 7.62% and 
15.38% respectively. These figures correlate well with the global resistance rates 
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as well as resistance in most of the Western countries like Spain, Italy, most of the 
American states and Columbia.(139- 145) Similar prevalence of Clarithromycin 
resistance (4.7%) has been observed in Gujarat, India.(146) Lower resistance seen in 
our setup may be due to decreased use of Macrolide drugs as empirical therapy in 
common infections and usage of Amoxicillin- Metronidazole combination as first 
line therapy for H.pylori infection. Clarithromycin resistance was assessed to be 
high ranging from 40-80% in other parts of India.  But the overall amoxicillin 
resistance rate in India (32.8%) is closer to the pattern seen in our study 
population. (15)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY  
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 Virulence of H pylori is variable with different strains and the infections 
produced by them are an upcoming burden due to the emergence of drug 
resistant strains. Hence this study was conducted to add on knowledge 
about the prevalence of various strains and their association with disease 
as well as drug resistance pattern in this region. 
 The study was conducted in the Department of Microbiology, PSGIMS&R. 
 Gastric biopsy samples were collected from 165 patients with gastro 
duodenal diseases undergoing Upper GI Endoscopy in Gastroenterology 
department in PSG Hospitals, Coimbatore after obtaining a written 
informed consent. 
 Three methods of identification of H.pylori infection namely Rapid urease 
test, Culture and Polymerase Chain Reaction were compared.  
 H.pylori isolates obtained from culture were tested for Clarithromycin and 
Amoxicillin susceptibility by E-test method. 
 Biopsy samples found positive by PCR for glmM gene were further 
characterized for cagA and VacA gene variants. Their correlation with 
disease pattern was analyzed. 
 Prevalence of H.pylori infection among the dyspeptic patients investigated 
in our hospital was 37% by PCR method. 
  Most of the patients who were infected fall within the age group of 30- 70 
years (75.4%) 
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 Male population, not only suffered from dyspeptic symptoms, but also was 
found to be infected with H.pylori (72%) more often than female (28%), 
ratio being 3:1. 
 H.pylori infection had a significant association with peptic ulcer disease 
rather than non ulcer dyspepsia (p<0.001) 
 Rapid urease test had better sensitivity of 93.4% compared to culture, but 
culture had the highest specificity. Culture had the highest positive 
predictive value (100%) while rapid urease test had a better negative 
predictive value. 
 Rapid urease test is cheap and easy to perform in day to day practice, 
making it an ideal screening procedure.  
 Culture required transport of biopsy sample in Brucella broth and plating in 
Chocolated Brucella agar with added antibiotic and incubation in 
microaerophilic atmosphere, in Anoxomat system. Culture, owing to its 
need for skilled techniques, special media & incubation conditions and time 
consumption, should be reserved for patients requiring antibiotic 
susceptibility testing. 
 Though PCR is an expensive method compared to RUT, it has the 
advantage of providing data on the virulence nature of the bacteria in 
individual patients, making it more informative on decision making 
grounds like need for treatment, need for follow up, etc. 
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 On analysis of virulence genes, cagA positivity was 60.6% in our study. 
There was a statistically significant association between presence of cagA 
gene and peptic ulcer disease rather than the non ulcer dyspepsia (p<0.05, 
odds ratio was 6 with 95% CI). 
 Prevalence of VacA s1 subtype was 72% and it was distributed only among 
the patients with pathological findings related to H.pylori infection. On the 
contrary 28% of the s2 strains were more often associated with non specific 
gastritis and normal endoscopic finding. There was a statistically significant 
correlation between the vacAs1 variant  and the disease manifestations 
(p<0.01) 
 VacAm1/2 variants showed no association with disease manifestation 
(p>0.05) 
 None of the patients included in this study were colonized with multiple 
strain. 
 Most of the VacA s1 cagA positive strains were associated with PUD and 
gastroduodenitis. This could be used as a virulence marker indicating that 
the patient harboring these strains need a rigorous eradication  therapy and 
follow up to avoid severe manifestation of H.pylori infection. 
 In this study the resistance to Clarithromycin and Amoxicillin was 7.62% 
and 15.38% respectively. These two drugs maybe continued for use as first 
line therapy in our population 
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With the 37% prevalence of H pylori in this region among patients with 
gastro duodenal diseases, the currently used invasive procedures to detect H.pylori 
infection, the in-house rapid urease test was found to be cheap, easy to perform, 
quick and a point of care test with good sensitivity. Though cultivation and storage 
of these fragile organisms was a difficult task, almost 50% of the growths were 
subjected to AST. The results showed lower prevalence of resistance to 
Clarithromycin and Amoxicillin 7.62% and 15.38% respectively. Genetic analysis 
of VacA & CagA virulent genes and their subtypes turned out to be fruitful, 
emphasizing the need for their routine testing to identify the severity and 
administer antibiotics appropriately for eradication.  
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1) GRAM STAIN: 
Crystal violet: 
Crystal violet                          1.0gm 
5% sodium bicarbonate          1.0ml 
Distilled water                         99ml 
Grams iodine: 
Iodine crystal                        2.0gm 
Sodium hydroxide                10.0ml 
Distilled water                      90.0ml 
Acetone- 100% 
DILUTE CARBOL FUCHSIN- 1 in 10 dilution of strong carbol fuschin. 
2) BRUCELLA BROTH: 
 Brucella broth base (BD)     2.8gm 
 Distilled water                     100ml 
 Warmed slightly to dissolve the contents and adjusted to pH 7. Dispensed 
as 3ml each, in screw capped tube and autoclaved at 121oC for 15 minutes at 15 
lbs. 
2) BRUCELLA CHOCOLATE AGAR: 
Brucella agar base with added                   4.31gm  
Hemin and vitamin K(HIMEDIA)    
 
Distilled water                                            100 ml 
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 The above mixuter is autoclaved at 121oC for 15 minutes at 15 lbs 
and the cooled to 800C. Add 7 ml of sterile defibrinated sheep blood and 
hold at 800C for 20 minutes in waterbath. Cool to 45-500C and pour 20ml 
of this chocolate agar in the petridish to set. 
3) BRUCELLA CHOCOLATE AGAR: 
 Agar preparation is same as the above procedure. Just before the pouring of 
media, add the following pre-dissolved antibiotics and mix well. 
 Vancomycin           1mg/100ml 
 Polymyxin B          250 IU/100ml 
 Amphotericin B     0.5 mg/100ml. 
4) CHRISTENSEN’S UREASE AGAR: 
  Christensen’s urease agar base (HIMEDIA)    2.4gm 
Distilled water                                                  100ml 
pH                                                                     6.8 
           The above ingredients are mixed by boiling and sterilized by autoclaving at 
1210 C for 15 minutes. 
 Urea 40gm 
 Sterile distilled water 100ml 
 The above ingredients are mixed and sterilized by membrane filtration. 
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Mix 5ml of the urea solution in 100ml of autoclaved Christensen’s urease agar 
base when it cools to 50oC. Dispensed in tubes and allowed to cool in a slanted 
position. 
 
5) CATALASE REAGENT: 
             Superoxal             10ml 
             Distilled water      90ml 
             Store it in dark coloured bottle at 4oC 
6) OXIDASE PAPER: 
             Tetramethyl para-phenylene diamine dihydrochloride      1gm 
             Distilled water                                                                   100ml 
             Mix well and soak the Whatmann no. 1 filter paper strips in it. Dry the 
strips at room temperature in dark. Store it in dark coloured bottles. 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURES 

 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
 
I  Dr J Lavanya am carrying out a study on the topic: Isolation and characterization of Helicobacter 
pylori in Gastroduodenal disease at a tertiary care hospital’ 
 
as part of our research project being carried out under the aegis of the Department of microbiology 
 
(Applicable to students only): My / our research guide is: Dr J Jayalakshmi 
 
The justification for this study is: Helicobacter pylori is a rising burden in developing countries due to increased 
prevalence and upcoming drug resistance. 
 
 
 
The objectives of this study are: 
PRIMARY OBJECTIVE: 
1. Study the prevalence of virulence factors of H pylori and their association with disease pattern among 
patients in a tertiary care hospital. 
SECONDARY OBJECTIVES: 
1. To isolate and characterize H pylori from biopsy samples of patients . 
2. To compare various detection methods such as  Rapid Urease test , Staining, and PCR against culture 
“the gold standard method 
3. To Identify the prevalence of drug resistant strains in our population 
4. To identify the CAG and VAC genes and their association with the virulence state 
 
Sample size:  165 
 
Study volunteers / participants are (specify population group & age group): Patients undergoing Upper GI 
Endoscopy in Gastroenterology department. 
 
Location: ___PSG Hospital____.  
 
We request you to kindly cooperate with us in this study. We propose collect background information and other 
relevant details related to this study. We will be carrying out:  
 
Data collected will be stored for a period of __5___ years. We will not use the data as part of another study. 
 
Clinical examination (Specify details and purpose): NA 
 
Biopsy sample collection: 
Number of biopsy samples collected: 3 bits for this study apart from routine    
 
No. of times it will be collected: All 5 Gastric biopsy samples will be collected in a single Endoscopy.  
 
 
Whether biopsy sample collection is part of routine procedure or for research (study) purpose:   
 
1. Routine procedure   - 1-3 samples 
 
2. Research purpose    - 3 samples 
 
Specify purpose:  For Bacterial culture and PCR. 
 
Whether sample collected will be stored after study period:    No, it will be destroyed 
 
Whether sample collected will be sold:  No  
 
Whether sample collected will be shared with persons from another institution:  No 
 
Benefits from this study: Early and effective management of patients with H.pylori infection. 
 
Risks involved by participating in this study: Endoscopy procedure related risks only. No specific risk 
concerned to this study 
 
How the results will be used: For Dissertation purpose  
 
If you are uncomfortable in answering any of our questions during the course of the interview / biological sample 
collection, you have the right to withdraw from the interview / study at anytime. You have the freedom to 
withdraw from the study at any point of time. Kindly be assured that your refusal to participate or withdrawal at 
any stage, if you so decide, will not result in any form of compromise or discrimination in the services offered nor 
would it attract any penalty. You will continue to have access to the regular services offered to a patient. You will 
NOT be paid any remuneration for the time you spend with us for this interview / study. The information 
provided by you will be kept in strict confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be used for approved research 
purposes only. You will be informed about any significant new findings - including adverse events, if any, – 
whether directly related to you or to other participants of this study, developed during the course of this research 
which may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has been 
explained to me by the investigator/s. Having understood the same, I hereby give my consent to collect gastric 
biopsy samples from me. I am affixing my signature / left thumb impression to indicate my consent and 
willingness to participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI:  8754564994 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 

 
S.No AGE SEX ENDOSCOPIC 
FINDING 
RUT CULTURE PCR 
FOR 
glmM 
GENE 
CagA 
STATUS 
VacA 
SUBTYPE 
1 72 M Gastritis - - -   
2 53 M Gastritis + + + - s1m1 
3 32 F Gastritis + - -   
4 37 F Normal study - - -   
5 36 M Gastritis - - -   
6 55 F Normal study - - -   
7 29 F Gastritis + - -   
8 30 M Gastroduodenitis + + + + s1m1 
9 62 M Gastritis - - -   
10 
38 M 
Grade A reflux 
esophagitis - - -   
11 46 F Tropical sprue - - -   
12 37 M Gastritis - - -   
13 27 F Gastritis - + + - s2m2 
14 67 M Gastritis + + + + s1m2 
15 40 M Gastritis - - -   
16 47 F Gastritis - - -   
17 60 F Gastroduodenitis - - -   
18 70 M Duodenal Ulcer + + + + s1m1 
19 37 M Gastritis - - -   
20 21 M Gastritis - - -   
21 29 M Gastritis - - -   
22 59 M Gastritis - - -   
23 50 F Gastritis + + + + s1m2 
24 34 M Gastritis - - -   
25 75 M Gastritis - - -   
26 33 M Normal study + - -   
27 80 M CA Stomach + - -   
28 27 M Gastritis + + + - s1m1 
29 36 M Gastritis - - -   
30 19 F Gastritis + + + - s2m1 
31 66 M Gastritis - - -   
32 40 M Gastritis + + + + s1m2 
33 43 F Gastritis - - -   
34 31 M Normal study - - -   
35 57 F Gastritis - - -   
36 53 F Gastritis - - -   
37 50 M Gastritis - + + + s1m1 
38 50 M Duodenal Ulcer + + + - s1m1 
39 56 F Gastritis + + + - s2m2 
40 15 M Gastroduodenitis + + + - s1m1 
41 20 M Reflux esophagitis + - + - s2m2 
42 18 M Normal study - - -   
43 36 F Gastritis - - -   
44 54 M Gastritis - - -   
45 37 M Duodenal Ulcer + + + + s1m1 
46 57 M Gastritis - - -   
47 75 M Normal study - - -   
48 30 F Normal study - - -   
49 67 M Gastritis + + + + s1m1 
50 70 F Gastritis - - -   
51 55 M Gastritis - - -   
52 75 M Gastritis + + + - s2m1 
53 35 M Gastric polyp - - -   
54 60 M Gastritis + - + - s2m2 
55 37 F Gastritis - - -   
56 31 F Normal study - - -   
57 52 M Normal study - - -   
58 50 F Gastritis + - + - s2m2 
59 59 M Gastritis - - -   
60 30 M Gastritis - - -   
61 73 M Gastritis - + + + s1m1 
62 35 F Normal study + - + - s2m2 
63 63 M Gastritis - - -   
64 40 M Gastroduodenitis + + + + s1m1 
65 43 M Gastritis + + + + s1m2 
66 66 M Gastroduodenitis - - -   
67 41 F Gastroduodenitis + + + + s1m2 
68 53 F Gastritis + - -   
69 52 M Gastritis + + + - s2m2 
70 32 F Gastric Ulcer + + + + s1m1 
71 61 M Gastroduodenitis + + + + s1m2 
72 46 F Gastritis - - -   
73 20 M Gastritis - - -   
74 52 F Gastritis - - -   
75 60 F Gastric Ulcer + + + + s1m1 
76 23 M Gastroduodenitis - - -   
77 30 F Normal study - - -   
78 79 M Gastritis + - + - s1m1 
79 48 M Gastritis - - -   
80 65 M Gastroduodenitis + + + + s1m2 
81 56 M Gastritis - - -   
82 47 M Gastritis - - + + s1m1 
83 
90 M 
Esophageal 
diverticula - - -   
84 58 M Gastritis + + + - s2m1 
85 70 M Duodenal polyp - - -   
86 57 F Gastritis + - -   
87 55 F Gastritis - - -   
88 44 F Normal study - - -   
89 59 M Gastritis - - -   
90 60 M Gastritis + + + - s2m1 
91 42 M Gastritis - - -   
92 59 M Gastritis + + + - s2m2 
93 34 M Gastritis + - -   
94 54 M Gastritis + - -   
95 53 M Gastroduodenitis - - -   
96 51 M Gastritis + + + - s2m1 
97 47 M Duodenal Ulcer + + + + s1m1 
98 38 F Gastritis - - -   
99 60 F Gastritis - - -   
100 36 F Gastritis + + + + s1m2 
101 49 M Normal study - - -   
102 23 F Normal study + + + + s2m2 
103 57 F Gastritis - - -   
104 47 M Gastritis - - -   
105 50 F Gastric Ulcer + + + + s1m2 
106 49 M Gastritis + + + + s1m1 
107 62 M Barret esophagus - - -   
108 34 M Gastric Ulcer + + + + s1m2 
109 39 F Gastritis - - -   
110 73 M Gastritis - - -   
111 59 M Normal study - - -   
112 70 M Gastritis - - -   
113 66 M Gastritis - - -   
114 54 M Normal study - - -   
115 40 F Gastritis - - -   
116 62 M Duodenal Ulcer + + + + s1m2 
117 63 F Gastritis - - -   
118 27 F Gastritis - - -   
119 54 M Gastritis - - -   
120 35 M Gastritis - - -   
121 36 F Gastritis - - -   
122 45 M Gastritis + + + + s1m2 
123 60 F Normal study - - -   
124 37 F Gastritis - - -   
125 44 M Gastritis - - -   
126 54 M Normal study - - -   
127 56 M Gastric Ulcer + + + + s1m1 
128 54 F Gastritis + + + - s1m1 
129 55 M Gastritis - - -   
130 48 F Gastritis + + + + s1m2 
131 67 M Gastritis - - -   
132 39 M Normal study + + + + s2m1 
133 48 F Gastritis - - -   
134 15 M Gastritis + + + - s1m1 
135 46 M Gastritis - - -   
136 70 F Gastric Ulcer + - + + s1m2 
137 52 F Gastritis - - -   
138 31 M Normal study - - -   
139 78 F Gastritis + + + - s1m2 
140 77 M Gastritis - - -   
141 33 F Gastritis - - -   
142 56 M Gastric Ulcer + - -   
143 37 F Gastritis + + + + s1m2 
144 49 M Gastric Ulcer + + + + s1m1 
145 64 M Gastritis + - + + s1m1 
146 64 M Gastritis + - -   
147 20 M Gastritis + - + - s1m2 
148 23 M Gastritis - - -   
149 21 M Normal study + + + - s2m2 
150 71 M CA Stomach - - -   
151 45 F Gastric Ulcer - - -   
152 77 F Gastric polyp - - -   
153 57 M Gastritis + + + - s1m2 
154 61 F Gastritis - - -   
155 62 M Gastric Ulcer + + + - s1m1 
156 22 M Normal study - - -   
157 70 M Gastric Ulcer - - -   
158 53 M Gastric polyp - - -   
159 70 F Gastritis - - -   
160 65 F Gastritis + + + + s1m1 
161 65 M Gastritis + + + + s1m2 
162 44 M Normal study + + + - s2m2 
163 60 M CA Stomach - - -   
164 36 F Fundal polyp - - -   
165 60 M Gastric Ulcer + + + + s1m1 
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